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ABSTRACT 
 
Effect of Consuming Ground Beef of Differing Monounsaturated Fatty Acid Content on 
Atherosclerotic Cardiovascular Disease Risk Factors in Healthy Men. (December 2008)  
Xiaojuan Cao, B.M., Ningxia Medical College 
  Chair of Advisory Committee: Dr. Rosemary L. Walzem 
 
Atherosclerotic cardiovascular disease (ASCVD) is currently the most common 
cause of death in the United States. Some dietary factors contribute importantly to 
ASCVD and other factors can reduce risk of ASCVD. Oleic acid is a monounsaturated 
fatty acid (MUFA). Dietary patterns in which oleic acid contributes to a majority of 
dietary fatty acids are associated with reduced ASCVD risk. These beneficial effects are 
due to MUFA-induced lipoprotein profile changes such as decreases in low density 
lipoprotein (LDL) and increases in high density lipoprotein (HDL). LDL oxidation plays 
a central role in atherosclerosis development as it both initiates and propagates 
atherosclerosis. HDL is anti-atherogenic as it can attenuate LDL oxidation. HDLs are a 
class of diverse lipoprotein that varies in protein and enzymatic composition. The 
paraoxonase (PON) family of enzymes, especially PON1, is primarily expressed in the 
liver; PON activity in the circulatory system is associated with HDL. Both PON and 
HDL have been documented to be anti-atherogenic. Other factors such as homocysteine 
and C-reactive protein (CRP) can also be considered risk factors for ASCVD. However, 
studies of risk factors in healthy men who consume ground beef with a different content 
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of MUFA are lacking; hence, no conclusive evidence has established whether 
consuming a high amount of MUFA in the form of ground beef alters the development 
of atherosclerosis.  
The overall purpose of this study was to investigate whether the provision of 
ground beef with a fractionally higher MUFA content could lower or improve several 
ASCVD risk factors in men who consume ground beef. These risk factors include the 
metabolic indices of glucose, insulin and homeostasis model assessment (HOMA), 
inflammation risk factors of CRP and homocysteine and anti-risk factor of paraoxonase. 
The concentration of homocysteine was determined spectrophotometrically following 
separation by high pressure liquid chromatography (HPLC). Enzyme-linked 
imminosorbent assay kits that measured the CRP and insulin concentration in plasma. 
The significance of the results was determined by subjecting the data to ANOVA using 
the general linear model for repeated measurement (P<0.05).     
From this study, it can be concluded that MUFA has a beneficial effect of 
lowering risks as determined by metabolic indices and lipoprotein profile. Moreover, our 
study showed that different concentrations of MUFA in ground beef has no effect on 
PON1 activity, but that increased beef consumption generally reduces PON1 in 
association with increases in homocysteine concentration while improving indicators of 
glucose tolerance. 
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NOMENCLATURE 
 
ANOVA                      Analysis of Variance   
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NCEP                          The National Cholesterol Education Program 
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PON                            Paraoxonase 
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TG                               Triacylglyceride 
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CHAPTER I 
INTRODUCTION 
 
Cardiovascular disease (CVD) is the highest cause of mortality in the United 
States, killing almost 17 million individuals each year (1). Atherosclerotic 
cardiovascular disease (ASCVD) plays an important role in the development of CVD; it 
has a much higher rating as a causal factor than other independent risk factors such as 
cigarette use and hypertension (2). Currently, we know that ASCVD is a chronic disease 
that is characterized by the formation of atheroma (plaque) as the mature lesion. Lesion 
formation reflects progressive lipid accumulation in the large- and medium-sized arteries 
and is the fundamental pathological process in this disease. Chronic inflammation 
underlies ASCVD (2, 3). During chronic inflammation, the endothelial cells lining the 
arteries become injured and respond by inappropriate cell-signaling that propagates 
damage to the surrounding cell types and macromolecules, thereby leading to plaque 
formation in the intima and media of the artery wall (4). For example, pathological 
studies have revealed that oxidized low-density lipoprotein (ox-LDL) and inflammatory 
mediators such as monocyte chemotactic protein (MCP-1) can be found in the injured 
artery wall (2, 5). Further, studies showed that oxidative modification of LDL, either in 
the circulation or in the artery wall, plays a critical role  in the development of ASCVD 
(6, 7). Thus, oxidative stress within artery, the formation of ox- LDL and their  
____________ 
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accumulated ions within the subendothelium alter endothelial function and impair flow-
mediated vasodilatation, an index of vascular wall compliance and health (2, 8).  
Two potent lipoproteins, LDL and high-density lipoprotein (HDL) play 
important albeit usually opposite, roles in the development of ASCVD. In this regard, 
LDL can promote endothelial dysfunction, arterial injury and plaque formation (9, 10) 
and is commonly known as “bad cholesterol.” In contrast, HDL is commonly known as 
“good cholesterol,” as it mediates cholesterol efflux from the arterial wall and contains 
antioxidant enzymes such as PON1. In general, both increasing LDL concentrations and 
decreasing HDL concentrations increase the ASCVD risk (9, 10). Indeed, changes in 
circulating concentrations of both types of lipoproteins are independent risk factors for 
ASCVD. As an adverse risk factor, LDL-cholesterol (LDL-C) has been estimated to 
increase ASCVD risk by 4% for each 1.0 mg/dL increase (9). In contrast, every 1.0 
mg/dL decrease in HDL-cholesterol (HDL-C) increases ASCVD risk by 2% in men and 
3% in women (10, 11). The National Cholesterol Education Program (NCEP) in the 
Adult Treatment Panel III now lists low HDL-C concentration (Table 3) as an 
independent risk factor for ASCVD (12). Moreover, a high circulating concentration 
(>16 µM/L) of the amino acid homocysteine is also considered as a risk for ASCVD 
(13-15). Homocysteine is an oxidative stressor able to cause endothelial cell dysfunction 
and provoke chronic inflammation within arterial walls and, as a result, smooth muscle 
cell proliferation (16-18). C-reactive protein (CRP) is an acute phase reactant, and a 
concentration > 1.5 mg/dL indicates chronic inflammation within the vascular wall (19-
22), and CRP is a biomarker for increased ASCVD risk (23, 24). To assess the CRP 
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inflammation marker, the American Heart Association and the Centers for Disease 
Control and Prevention (AHA/CDC ) panel defined the cut-off CRP value  for  ASCVD 
risk as 1.0 mg/dL for “low risk,” 1.0-3.0 mg/dL for “average risk” and >3.0 mg/dL for 
“high risk” (25). 
Central obesity is a characteristic associated with risk for metabolic syndrome, 
i.e. diet-induced insulin resistance (normal glucose, high insulin) and altered lipoprotein 
metabolism that increase the risk for ASCVD (14). Epidemiological studies suggest that 
MUFA may stimulate β-cells in the pancreas to secrete insulin (26, 27).   
Studies showed that oxidized LDL-C could be recovered from the artery wall 
(28). The presence of oxidized lipids in LDL-ox particles—so called peroxide “seeding,” 
—can initiate inflammation in the artery wall. This inflammatory process can be 
inhibited by normal HDL (5, 29, 30). Hence, HDL possesses antioxidant activity and 
serves an anti-inflammatory function. How HDL mediates these activities is not fully 
understood. HDL is a heterogeneous class of lipoprotein particles. HDL can be classified 
by particle size, density and apolipoprotein content. In general, HDL is a cholesteryl 
ester (CE)-rich lipoprotein. A primary function of HDL is to carry out reverse 
cholesterol transport from peripheral tissues to the liver for reuse or disposal in bile. This 
process limits the inflammation in the vascular wall (29-31). Recent reviews illustrated 
how the antiatherogenic function of HDL is related to its apolipoprotein composition and 
intrinsic enzyme activity (31, 32). HDL particles contain as many as 48 proteins that can 
be grouped according to functions such as “lipid metabolism” and “acute phase 
response” (32). Variation in the apolipoprotein content can cause a variety of effects 
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depending on the HDL subclasses. Different subclasses of HDL participate differentially 
in ASCVD mitigation and progression.  
One scheme classifies HDL subclasses by particle size (diameter), density and 
apolipoprotein composition (33-35). Based on this scheme, small (5.5 to 9.5 nm) HDL 
that are more dense (1.125 g/mL < d < 1.21 g/mL) are called HDL3. If the particles are 
larger (9.5 to 12.0 nm) and less dense (1.063g/mL < d < 1.125 g/mL), they are termed 
HDL2 (33). Some studies concluded that HDL3 are more responsible for HDL’s anti-
atherogenic function (31, 32). The amount of HDL2 and HDL3 or the ratio of these two 
HDL subclasses is considered as a diagnostic test for ASCVD risk (36).  
That dietary fat influences plasma lipoprotein profiles and that certain profiles 
are linked to risk of ASCVD is well known. Saturated fatty acids (SFA), especially 
palmitic acid (16:0) and myristic acid (14:0), elevate total and LDL-C, whereas the SFA 
stearic acid (18:0) had no effect on LDL-C concentrations (37). The MUFA oleic acid 
(18:1) reduces total and LDL-C concentrations (38). Therefore, substitution of MUFA 
for SFA is expected to produce lower cholesterol concentrations (39). However, HDL-C 
concentration reduction by dietary factors can adversely affect ASCVD risk. High 
carbohydrate and low fat intake increases the concentration of triacylglycerol (TG), 
whereas it decreases that of HDL-C in blood (40-42). This pattern of dyslipidemia is 
found in individuals with insulin resistance (metabolic syndrome X) (43). Compared to 
carbohydrate, oleic acid has the effect of lowering TG and increasing HDL-C (44). The 
ratio of total cholesterol (TC) to HDL-C is considered by many to be a better index of 
ASCVD risk than LDL-C or HDL-C because it considers relative changes in HDL-C in 
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its risk assessment (45). Stearic acid, which has a neutral or modest LDL-C lowering 
effect, has a modest HDL-C elevating effect, and as a result, stearic acid reduces total-
C:HDL-C (46). Beef fat consists mostly of the SFA stearic acid and palmitate (25-30%) 
and MUFA (47). Oleic acid-enriched beef consumed by mildly hypercholesterolemic 
men significantly increased the concentration of the primary HDL apolipoprotein, apoA1 
(48).  
In humans, the effects of a protein-rich diet for the development of 
atherosclerosis have not been clearly demonstrated. Soybean protein had a beneficial 
hypocholesterolemic effect as shown by a decreased serum concentration of LDL and an 
increased concentration of HDL (49). Casein is a protein that is found in milk that has a 
similar effect on plasma lipids as soybean protein (50). However, animal protein 
consumption increases TG compared with plant protein consumption, and thus increases 
ASCVD risk (51, 52). The amount of protein intake influences blood cholesterol. Infants 
with severe protein malnutrition show significant weight loss associated with a decrease 
in serum fatty acid (53). Chronic renal failure patient without a protein restrict diet 
exhibited a hypertriglyceridemia and an increase risk for development of atherosclerosis 
(54). Methionine is a sulfur amino acid, which have been demonstrated has atherogenic 
effects (55, 56). A good diet source of methionine is animal protein, thus, these 
investigations suggest that a higher intake animal protein could increase ASCVD risk. 
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CHAPTER II 
LITERATURE REVIEW 
  
Numerous risk factors contribute to the development of atherosclerosis and CVD. 
LDL oxidation plays a central role in the initiation and progression of atherosclerosis. In 
order to study the effect of consuming ground beef with different MUFA content on risk 
factors of ASCVD in healthy men, it is important to understand what atherosclerosis is, 
how it happens and what process components risk factors estimate within the disease 
process. This literature review gives a brief description of the development of 
atherosclerosis and the basis for the putative roles of several risk factors in the 
development of atherosclerosis. 
The development of atherosclerosis  
The development of atherosclerosis is a slow and continuous process that is 
associated with the accumulation of lipids and fibrous elements to form plaque in the 
large arteries causing them to narrow. Impaired blood flow through narrowed arteries 
reduces the oxygen-rich blood supply to the body, especially the heart and brain. 
Atherosclerosis is the main contributor to CVD, which leads to heart attacks, strokes or 
even death in western countries. Previous evidence revealed that chronic inflammation 
and immune response contribute to ASCVD development (3, 57). The mechanism of 
atherosclerosis is complex. The pathological development of atherosclerosis (Figure 1) 
has been revealed as a series of protective responses to injuries of endothelial cells in the 
artery wall (5). Oxidatively modified lipids formed in LDL (Ox-LDL) while present in 
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the intima initiate atherosclerosis by damaging endothelial cells that signal inflammatory 
cells (monocyte and/or macrophage) migration through cell-derived adhesion and 
chemotactic factors. Conversion of monocytes into macrophages that subsequently 
engulf Ox-LDL and so become lipid-laden foam cell that constitutes a key element of 
the fatty steak. Endothelial cells response to Ox-LDL injury that stimulates 
inflammatory cells also stimulates smooth muscle cell migration and differentiation, 
which contribute to the fatty steak more maturation. This  sequence of events can be 
verified by in vivo and in vitro experiments (4, 21). The lipid core of fatty steak is 
surrounded by a thin fibrous cap that contains reduced collagen, smooth muscle cells and 
macrophages that make the complex plaque vulnerable to erosion or rupture causing a 
series of events (58). Necropsy studies demonstrated that 60-80% of ASCVD deaths 
occurs as a result of fibrous-cap rupture (59). With time, the fibrous fatty plaque elevates 
the artery wall and intrudes into the arterial lumen reducing its diameter and affecting 
blood flow, oxygen and nutrient transport. During this inflammation process, non-
laminar shear flow and ox-LDL reduced the production of nitric oxide (NO)—a 
chemical with vasodilatation function—from endothelium cell, the result of reduced NO 
also was shown to have atherogenic activity (60). Foam cell death forms a necrotic core 
of lesion, while smooth muscle cell proliferation and differentiation causes the 
development of the fibrous fatty streak plaque in artery wall (58). Epidemiological 
studies have identified numerous risk factors associated with this injury and response; 
these risk factors can be group into genetic factors (high LDL, low HDL, high blood 
pressure, high level homocysteine, high CRP) and environmental factors (high-fat diet, 
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smoking and lack of exercise), and these risk factor can combine to modulate 
inflammation process (2). 
Lipoprotein 
Lipoproteins have been related to disease such as atherosclerosis over the last 
several decades. Lipoproteins are macromolecules that contains both lipids and proteins 
at variable ratios, densities and sizes (61). The common nonpolar components of 
lipoprotein are cholesterol ester (CE) and TG. Because the CE and TG are hydrophobic, 
they need to be transported within the amphipathic structures of lipoprotein to make 
them miscible with the aqueous fluid components of blood plasma (62, 63). Their major 
role in the body is transport of lipid and lipophilic nutrients in the body. Apolipoproteins 
are also associated with lipoprotein, and serve both structural and regulatory functions 
within the particles. There are at least nine types of apolipoproteins. Five major classes 
of lipoproteins are commonly discussed, with individual classed based on particle 
density, component content and diameter (large to small): (Table 1) chylomicron (CM), 
very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), LDL and 
HDL (62). 
Cholesterol is involved in three pathways in body (Figure 2). These are the 
exogenous pathway (CM transfer cholesterol from intestine to liver), the endogenous 
pathway (VLDL and LDL transfer cholesterol from liver to the body) (62, 63) and 
reverse cholesterol transport (HDL transfer excess cholesterol from body back to the 
liver for disposal). Dietary cholesterol and fat are assembled into CM within the 
enterocytes and transported through the lymph prior to release into the general 
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circulation (63). CM are TG-rich, large and the least dense of the lipoproteins that 
functions to transport dietary lipids to peripheral tissues and ultimately liver. In liver, 
cholesterol and TG are assembled into VLDL and serve to transport lipid nutrients to 
muscle and adipose tissue. Their five different major apolipoprotein (ApoB100, ApoCI, 
ApoCII, ApoCIII and ApoE) (64). After VLDL transport TG and other lipids to muscle 
and adipose, they lose part of apolipoprotein and become denser LDL (62). LDL 
contains a high percentage cholesterol and CE with apolipoprotein (ApoB100, ApoE, 
ApoC). ApoB100 can bind to LDL receptor—which is located on cell surface—to allow 
LDL carry cholesterol in the blood stream (65). Once apolipoprotein binds to the LDL 
receptor, LDL enters into the cell and then is endocytosed, apolipoprotein is degrade to 
its amino acid, and CE is converted to cholesterol, these components can then be used by 
the cell (62, 65, 66). HDL contains 50% protein; therefore, it has a much higher density 
than other lipoproteins; it functions to transport excess cholesterol from tissue and 
returning it to liver.                                                                                        
Apolipoprotein                                                                                                             
Apolipoproteins are associated with lipoproteins and act as structural elements, 
receptor ligands, enzymatic and transfer protein activities that mediate lipoprotein 
metabolism. There are at least nine types of apolipoprotein. ApoB48 is a short form of 
ApoB100. In humans, ApoB48 can be found in chylomicron; it can not bind to its receptor 
without another apolipoprotein. In contrast, ApoB100 is the long form of ApoB and, is 
not only found in VLDL, but is also found in IDL and LDL which are the end products 
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of VLDL metabolism.                                                                                                   
LDL and LDL oxidation                                                                                                                                 
            LDL is a major transporter of cholesterol to peripheral tissue through the 
circulatory system. Hence, an elevated concentration of LDL causes its entry rate 
through the endothelium cell junction into the intima to increase, leading to endothelial 
dysfunction. This dysfunction alters vascular vasomotion tone, which contributes to 
ASCVD with increasing age and elevated LDL cholesterol concentration (67, 68). Some 
evidence indicates that oxidatively modified LDL in the artery wall is likely to have a 
key role in the development of atherosclerosis (69). All lipoproteins are susceptible to 
oxidation because of their fatty acid composition; however, LDL is most susceptible to 
lipid oxidation (70). The structural and biological properties of LDL are altered by the 
oxidation reaction (71, 72). LDL is CE-rich, of variable particle size, and consists of 
apolipoprotein of ApoB100 and a smaller amount of ApoCIII and ApoE. ApoB is a 
receptor for LDL binding in the pathway of metabolism (62). Some research indicates 
that small, dense LDL are associated with atherosclerosis vascular disease (73).                     
            Phospholipids are a major lipid of LDL. Oxidized phospholipids can be 
atherogenic and are formed when LDL undergoes oxidation. LDL lipid peroxide content 
is an indicator of the balance of pro- and anti-oxidative balance in the body, including 
the ability of HDL to exert sufficient antioxidation activity to protect LDL from 
oxidation in vivo. The conjugated dienes formed during the oxidative reaction can be 
used to measure the LDL lipid peroxide content (74). Conjugated dienes are measured 
spectrophotometrically, with the oxidative stability of LDL described by lag time to 
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initial conjugated diene formation, and propagation rate of that free radical reaction per 
hour under standardized assay conditions (6, 75, 76). In biochemical terms, LDL 
oxidation is a free radical-driven chain reaction where polyunsaturated fatty acids are 
converted to lipid peroxides that easily decompose to many products, including 
biologically active aldehydes. The in vitro assay of LDL oxidation detects a product of 
LDL oxidation, conjugated diene (CD), at 234nm and the time to a measurable increase 
in CD (lag time) and the rate of CD accumulation (propagation rate) gives an indication 
of LDL susceptibility to oxidation.                                                                               
Insulin resistance                                                                                                                             
            As known for several decades (Himsworth, 1936), insulin resistance is associated 
with the increasing risk of ASCVD (77). Insulin resistance, is a key component of what 
has been come to be known as metabolic syndrome X. Metabolic syndrome X consists 
of a characteristic constellation of risk factors for heart disease that include 
hyperglycemia (high triglyceride > 150 mg/dL), low HDL-C (< 40 mg/dL for man and 
50 mg/dL for woman), insulin resistance (high fasting blood glucose > 110 mg/dL), 
central obesity and hypertension (130/85 mmHg or higher) (14, 78, 79), NCEP defined 
metabolism syndrome as presence any three of these five risk factors. Insulin resistance 
can be affected by both genetic and environmental factors. environmental factors are 
modifiable and include physical activity, dietary intake, and most especially 
carbohydrate and fat content and composition (14). Epidemiological studies indicate that 
dietary MUFA stimulate β-cell  insulin secrete (26, 27), suggesting that increased 
MUFA intake can delay the onset of frank diabetes in insulin resistant individuals. 
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Homocysteine 
Hyperhomocysteinemia is characterized by a high plasma concentration of 
homocysteine and is an independent risk factor for ASCVD including cerebral and 
peripheral vascular disease. Early evidence of the pathological development of 
atherosclerosis in hyperhomocysteinemia was demonstrated in 1969 in three children 
with a genetic defect in homocysteine metabolism (56). Many epidemiological studies in 
populations lacking genetic defects in homocysteine metabolism demonstrated that 
elevated blood concentrations of homocysteine have a relationship with the development 
of atherosclerosis. The mechanism by which homocysteine induces the development of 
atherosclerosis is not fully understood. The probable mechanism involves homocysteine-
induced endothelial cell dysfunction and promotion of blood clotting. Cell culture 
studies indicate that  homocysteine, a sulfur-containing amino acid, has a role in 
endothelial injury and stimulates smooth muscle cell proliferation (16-18). A high 
homocysteine concentration was suggested to cause endothelial injury as a consequence 
of hydrogen peroxide generation (80). Further study indicated that normal endothelial 
cells function to modulate the adverse effects of homocysteine by releasing NO and 
forming S-No-homocysteine (81, 82). Thus, homocysteine’s adverse effect in vascular 
tissue may cause the production of NO, leading in turn to dysfunction endothelial cells 
due to the formation of the S-NO-homocysteine. 
Homocysteine is an endogenous amino acid that can be converted by dietary 
methionine to cysteine or produced in body via remethylation and transsulfuration 
pathway (83) (Figure 3). Thus, elevated homocysteine concentrations result from the 
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effects of many factors, including diseases such as chronic renal failure, cancer and 
genetic defects in relevant enzymes, physiological factors such as age and sex and 
environmental factors such as smoking, coffee consumption and dietary adequacy of 
folic acid, vitaminB6 and B12 (84, 85). Thus, dietary and lifestyle factors can modify the 
concentration of homocysteine in plasma.  
C - reactive protein   
CRP is an acute phase reactant as its concentration rises during inflammatory 
episodes that occur in the body (21). Measuring and charting CRP values can prove 
useful in determining disease progress or the effectiveness of treatments (23, 24). CRP is 
therefore a marker of inflammation. It was recently discovered that CRP also plays a role 
in heart disease (19, 20). Research suggests that an elevated basal concentration of CRP 
is closely related to risk of  hypertension and cardiovascular disease (21); therefore, 
measurement of CRP may be a good way to determine the risk of ASCVD.  
The amount of CRP produced by the body varies in each individual, and its 
concentration can be increased by factors such as smoking and high blood pressure, 
whereas weight loss and exercise are associated with reductions in CRP concentrations 
(24, 86). An epidemiological study indicated that CRP can be used as an independent 
risk index for ASCVD and also for the possible future development of ASCVD (24). 
CRP can be used as an inflammation marker to test ASCVD risk, even in healthy people, 
because it is a stable molecule. Clinical evidence indicates that  the concentration of 
CRP  is more stable for over a five-year period than other risk factors (87-89). 
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HDL                                                                                                                          
Epidemiologic and clinical studies have identified a multitude of risk factors for 
ASCVD, and low HDL concentrations have emerged as the strongest predictors for the 
disease (2, 90, 91). Acceleration of ASCVD development in individuals with low plasma 
HDL concentrations is the result of its biological role in circulation (92). The well 
known anti-atherogenic property of HDL is a result of its role as a lipid transporter in the 
reverse cholesterol transport pathway—HDL transports excess cholesterol from 
peripheral tissues to the liver, and its associated enzymatic and transfer protein activities, 
including the enzyme paraoxonase, that are able to destroy oxidized lipids (93, 94). In 
addition, HDL is believed to protect against atherosclerosis by inhibiting the oxidative 
modification of LDL (29, 30, 93). The induction of adhesion molecules and monocyte 
chemoattractants that facilitate the formation of foam cells was shown to both protect 
LDL against oxidation and to attenuate the biological activity of oxidized LDL (95). 
HDL has the ability to retard LDL oxidation in vitro as was confirmed in HDL gene 
knockout mice (96). However the mechanism by which HDL protects against 
atherosclerosis is not fully known. HDL is a diverse particle class in which individual 
HDL particles contain varying amounts of apolipoproteins and enzymes (97). The 
antioxidant and anti-atherogenic properties of HDL have been attributed to the various 
proteins associated with HDL (93, 95). The protective effect of HDL against the 
development of ASCVD appears to be complex. Most research has focused on 
identifying and characterizing the enzymes and proteins responsible for HDL’s anti-
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atherogenic propensities. PON1 is one such enzyme that is believed to contribute to the 
protective effects of HDL (98).      
Paraoxonase 
Paraoxonase is a family of enzymes, and PON1 is primarily expressed in liver 
and found in the circulatory system where its association with HDL-C and ApoA1 has 
been documented to be related to its anti-atherogenic ability (99-101) through its ability 
to protect of lipoproteins and arterial cells against oxidation (102) (Figure 4). In vivo 
studies of PON1 knockout mice and transgenic mice suggest that this protective effect 
may contribute to PON1’s ability to attenuate the oxidative modification of lipoprotein 
(96, 103, 104). Moreover, low PON1 activity is found in diseases known to provoke 
oxidative stress disease such as systemic lupus erythematosus, chronic liver diseases, 
renal dysfunction and diabetes (99, 105-108). Clinical evidence confirmed PON1’s 
protective effect by showing that low serum PON1 enzyme can occur in subjects with 
ASCVD and immunostaining for PON1 confirmed that PON1 has the anti-atherogenetic 
activity (109, 110). The statistics study of the relationship between PON1 activity in 
ASCVD and non-ASCVD patient is a remarkable (111). The mechanism of PON1 
retardation of atherosclerosis development is unclear, although previous study has 
documented that the mechanism of PON action by hydrolysis of LDL-associated 
phospholipids and CE hydroperoxide contributes to the development of atherosclerosis 
(112). 
PON1 concentrations can be altered by environmental or lifestyle factors. Diet 
fatty acid composition alters serum PON1 activity (113). For example, used cooking oil 
 
 16
or trans fat lowers serum PON1 activity, and oleic acid can elevate serum PON1 (114-
116). Moreover, fat alteration of PON1 activity was verified in mice model by showing 
that is a high-fat diet reduced PON activity and the anti-atherogenic effect compared to a 
low-fat diet (117, 118). However, studies of PON1 activity in healthy men consuming 
ground beef rich in oleic acid are lacking. 
Dietary composition and lipid profile  
Of the environmental risk factors that contribute to ASCVD, dietary factors can 
be controlled. Previous studies (42, 119-122) have shown that the composition and 
amount of dietary carbohydrates, fatty acids, proteins, amino acids, and minerals (iron) 
and vitamin affect the blood lipoprotein profile in humans and experimental animals. 
The effects of changes in dietary fatty acid (SFA and MUFA) composition and non-fat 
nutrient (protein, methionine and B-vitamins) on serum lipid profile changes is discussed 
in the following sections.  
Saturated fatty acid  
Epidemiologic studies indicated that a high intake of SFA is associated with a 
high risk of ASCVD (123). The mechanism by which an increase in SFA intake may 
provoke atherosclerotic progression, included elevations in the concentration of total and 
LDL-C (124, 125). Palmitic acid (16:0) and myristic acid (14:0) were  more atherogenic 
and increased total cholesterol and LDL-C, whereas the SFA stearic acid (18:0) had no 
effect on LDL-C concentrations (37). The increase in LDL concentration by high SFA 
intake is caused by retardation of the activity of LDL receptor in liver (126), delaying 
particle clearance and increasing the oxidative susceptibility of the lipoproteins (6). 
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Furthermore, a high intake SFA may stimulate atherosclerosis by adhesion molecules. 
Importantly, individual SFA have different effects on the HDL-C. For example, lauric 
acid (12:0) decreases total-C: HDL-C, whereas myristic acid and palmitic acid increase 
its value (37). 
Monounsaturated fatty acid  
MUFA have the beneficial effect on lowering atherogenic risk (127). A diet with 
high MUFA content decreases total cholesterol by 10% and LDL-C by 14% compared to 
the “step II” diet containing a low, 25% dietary energy (DEI), fat diet designed to 
provide 7% DEI as SFAs, 12% DEI of MUFAs) (128). Furthermore, replacing a SFA 
diet with a high MUFA diet has a positive dose-dependent effect on lowing plasma 
cholesterol especially LDL-C concentration without changing the HDL-C concentration 
(129). Many studies have investigated mechanisms of MUFA’s proposed mechanisms 
for anti-atherogenic effects. These studies indicated that a high MUFA diet decreases 
ASCVD risk by attenuating LDL oxidation which has an atherogenic effect (130). 
Oxidation of LDL promotes atherogenesis in several ways: 1) it stimulates adhesion and 
chemotactic factors that cause the accumulation of inflammatory molecules (131), 2) it 
stimulates platelet activating factor accumulation thus promoting a thrombogenic effect 
(132) and 3) it stimulates the macrophage scavenger receptor that increases foam cell 
formation (71). 
Protein  
Epidemiological study has revealed that dietary protein intake may correlate with 
atherosclerosis. The effect of dietary protein on the development of atherosclerosis is 
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dependent on its source. Soy protein and lean fish were shown to have a beneficial 
association, lowering risk of atherosclerosis (133, 134) as a result of protective changes 
the lipoprotein profile (135). In contrast, casein appeared to elevate ASCVD risk. 
Animals protein have more positive effect for raising ASCVD risk compared to soybean 
protein (135, 136). Although animal protein increased affected atherosclerosis by several 
studies, there was no association between dietary protein and heart disease in other 
studies (137). Also, a study demonstrated that the relationship between nutrients of 
carbohydrate, fat and cholesterol was more important than the amount or nature of 
protein (138). A recent review indicated that there are still many areas of diet and heart 
disease that need to be addressed (119).  
Methionine and vitamin B  
The effect of methionine on the development of atherosclerosis is well illustrated 
(55, 56). Methionine increases plasma lipid concentrations, which may contribute to 
endothelial cell injury or dysfunction as confirmed in a rabbit study in which increases in 
dietary methionine and cholesterol led to myocardial fibrosis (139). Methionine is 
enriched in animal protein and is the only dietary source of homocysteine, which is 
partly responsible for atherogenic effects. Methionine metabolism in the body involves 
several B vitamins. Previous studies indicated that deficiencies of vitamins B6, B12 and 
folate are associated with risk of atherosclerosis by increasing plasma homocysteine 
(140, 141). Although other studies showed little evidence for this relationship (142, 
143). Vitamin B6, B12 and folate acid are essential cofactors for homocysteine 
metabolism via the remethylation or transsulfuration pathway (144). Folate can decrease 
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the hyperhomocysteinemia that causes endothelial cell dysfunction by induction of 
adhesion molecules (145, 146). In dietary intervention studies, elevated plasma 
homocysteine concentration was lowered by a daily supplement of 1 mg of folic acid 
and 5–100 mg vitamin B6 (147). 
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CHAPTER III  
MATERIAL AND METHOD  
 
Subjects 
28 healthy men (Texas A&M University faculty and staff) were recruited for this 
study. Originally, 30 men were recruited but 2 men were excluded for personal and 
health reasons. Subjects were eligible to participate if they had a fasting serum 
cholesterol concentration < 260 mg/dL; were between the ages of 30 and 60 yr, had no 
restriction of diet and no current medication, and had no history of ASCVD, diabetes, 
liver disease, kidney disease or cancer. All subjects were given a blood test to exclude 
diseases indicated. These blood tests included plasma lipid profile (total cholesterol, 
LDL-C, HDL-C and triglycerides), glucose, liver function test (aspartate 
aminotransferase, alanine aminotransferase, alkaline phosphatase, bilirubin, albumin) 
and kidney function test (blood urea nitrogen, protein, major minerals). All subjects were 
required to be nonsmokers. Subjects provided written informed consent and were 
instructed to maintain regular activities and body weight (initial bodyweight were 91.3 ± 
2.2kg). All 28 subjects finished three dietary phases in a crossover design. This study 
sample size was determined by statistics power calculations based on LDL-C and CRP 
and LDL diameter results as reported by Smith et al (48). The power calculation 
indicated that based on serum cholesterol concentration, at least 21 subjects would need 
to complete the treatment period (power = 0.79 at α = 0.05).   
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Overall experiment design  
The overall experimental design was a randomized complete block (RCB), 
crossover and repeated measured (Figure 5), single-blinded design. Briefly, the initial 30 
healthy men were randomly and evenly divided into two groups (block). Then three 
ground beefs (treatment) of low MUFA, mid MUFA and high MUFA content were 
randomly assigned within each group for 5-wk durations, followed by crossover to a 
different diet after consuming the habitual diets for a 3-wk washout period following 
each of the three treatments. For each subject, the habitual diet (baseline) was used as 
control for comparison with the treatment diet (final). Finally, two subjects (subjects 3 
and 23) were excluded for as personal and health reason to give a final number of 28 
subjects. As these two subjects were from two separate groups, the study still met the 
RCB design. 
The total duration of this experimental design was 24-week (Figure 6). Each test 
ground beef was consumed for 5 weeks, followed by a 3 week habitual diet washout 
period prior to crossover to the next test ground beef diet phase. Prior to each diet phase, 
and once during each phase, participants completed a four-day record that included one 
weekend day of their habitual diets. All blood samples were taken before and after 
consumption of each test ground beef diet.  
Each subject involved in this study was blinded to diet assignments. Body weight 
and diet were recorded at baseline and final. DEXA Body fat was determined at pre-
study (28.2%) and post-study (27.8%). Energy change was calculated during the course 
of treatment to provide more information of the effect of diet as a factor in measured 
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variable. All subjects were instructed to maintain their regular activity and to restrict 
exercise and physical activities and to avoid making any special efforts toward changing 
their weight. Prior to each diet phase, and once during each phase, participants 
completed a 4-day record that included one weekend day of their customary or habitual 
diets (Table 2). The dietary record provided additional information about energy source 
and was analyzed by a registered dietitian to determine the quantity of calories being 
consumed from protein, carbohydrates and fat, and amount of other components in the 
diet, including cholesterol, vitamins, and mineral. The fatty acid compositions of diet 
and plasma at each control and treatment phase were determined. Two kinds of contact 
method were used in this study, E-mail and telephone, to encourage participation to 
complete this study. 
Diet 
In each dietary phase, the participants consumed five 114 g (4oz) ground beef 
patties with a final fat content of 24% by weight. Test ground beefs differed in their ratio 
of MUFA: SFA. The “low MUFA” test ground beef MUFA: SFA was 0.71, of the “mid 
MUFA” test ground beef MUFA: SFA was 0.83 and the “high MUFA” test ground beef 
MUFA: SFA was 1.10.  
The experimental diet was provided by Texas A&M Rosenthal Meat Science & 
Technology Center from carcasses of Angus cattle fed either a corn- or a hay-based diet. 
The tested ground beef lean and fat trim were mixed to make the MUFA: SFA ratio of 
0.71 (lean and fat trim from 20 mo of age, hay-fed steers,), 0.83 (lean from hay-fed 
steers, fat from 500-kg corn-fed steers) and 1.10 (lean and fat trim from a 24 mo of age, 
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600-kg corn-fed steers). The tested ground beef patties were prepared with appropriate 
ratios of MUFA: SFA and stored frozen. A single patty in a single meal was considered 
as replacement of regular meat. On the day of initial blood sampling during each phase, 
participants received an unlabeled box containing all of the patties for each phase. The 
participants cooked patties themselves. The diet fatty acid composition of the 
participants habitual diet was determined by calculation from daily record and tested 
ground beef in this study is shown in Table 2. 
Blood draw and storage  
All blood samples were collected from the brachial vein at each phase. Plasma 
was harvested from blood collected into Vacutainer® tubes containing EDTA to prevent 
blood clotting and held on ice prior to centrifugation within two hours. Serum was 
harvested from blood collected into Vacutainer® tubes with clot-activating inserts. 
Blood was allowed to clot at room temperature for 1h prior to placement on ice until 
centrifuged within 3 h of collection. Both plasma and serum were separated from the 
cellular elements of blood by centrifugation at 2,000 × g for 15 min at 4 ºC. Resulting 
plasma or serum supernatants fractions were transferred to a clean, labeled storage vial 
and held at –80ºC prior to use. Prior to initiation of the test period, and at end of each 
treatment phase, blood was drawn from participants on two non-consecutive days.      
 Laboratory assay method  
Plasma total lipoproteins were isolated as the d < 1.2 g/mL fraction of plasma. 
The plasma total cholesterol was used with value for relative cholesterol distribution to 
calculated VLDL, LDL and HDL-C.  The quantitative assay of homocysteine, CRP, 
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glucose, insulin and paraoxonase was determined using serum. Homocysteine was 
assayed by using HPLC, insulin and CRP by ELISA kit and glucose assay by an 
enzymatic assay kit (Sigma Chemical Co., St. Louis, MO). Paraoxonase assay was 
assayed by spectrophotometry. Paraoxonase was assayed in serum, not plasma because 
paraoxonase requires Ca2+ for activity and to stabilize the enzyme, Because EDTA 
inhibits blood clotting by Ca2+ chelation, EDTA-plasma samples can inhibit its activity 
(148).  
Glucose assay 
Glucose was measured using an enzymatic assay kit (Sigma Chemical Co., St. 
Louis, MO).  
Insulin assay 
Serum insulin was assayed using a commercially available ELISA kit according 
to the manufacturer’s instructions (Millipore, Cat. # EZHI-14K). This method was based 
on the sandwich ELISA principle (Figure 9). The amount of each serum sample was 
measured in duplicate and quantified by measurement of absorbance at 450 nm using 
spectrophotometer.  The insulin concentration was calculated using a standard curve that 
was prepared in the same assay using manufacturer supplied insulin standards. 
HOMA calculation method 
           The homeostasis model assessment (HOMA) method evaluates both insulin 
resistance and the likelihood of pancreas dysfunction (insulin secretion) to determine 
glucose regulation in an individual (149). These values were used to test the effect of the 
consumption of different test ground beefs on insulin resistance and insulin secretion.  
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Insulin resistance index (IRI) = (FI (U/ml) × FG (mmol/L)/22.5  
β-cell function index (β-CFI) = (20× FI (µU/ml))/ (FG (mmol/L)-3.5)    
Where: fasting insulin is FI and fasting glucose is FG             
Homocysteine assay  
Chromatography conditions 
All HPLC solvents filtered through a 5-µm pore size filter (Sigma-Alcorich, 
58230-U Col: 86651-05 SUPELCOSIL™ LC-18 HPLC Column) and sparged with 
helium before use. To prepare solvent A, 5.443 g sodium acetate trihydrate (NaAc·3 
H2O) and 0.8 g triethanolamine was dissolved in 2 L HPLC H2O. This solution was 
adjusted to pH 7.2 ± .01 at room temperature with acetic acid or sodium hydroxide. Then 
8 ml tetrahydrofuran was added with mixing. Solvent B was prepared by mixing 200 mL 
of 100 mM NaAc·3 H2O with 2L HPLC H2O. The pH was adjusted to 7.2 ± .01 at room 
temperature, and 400 mL methanol and 400mL methyl cyanide (CH3CN). Solvent C 
was H2O: methanol (1:1). Due to the “lag” in the gradient system, the washout procedure 
required that the gradient be commenced for 2 h with solvent C at flow rate 0.8 mL/min. 
Re-equilibration required use of a gradient for 30 min with solvent of A and B 
(86%:14%) at flow rate 0.8 mL/min. Temperature were set at 4º C and excitation and 
emission were set at 340 nm and 450 nm, respectively. 
Procedure 
The concentration of homocysteine was measured by fluorescence detection 
using o-phthalaldehyde and 2-mercaptoethanol (OPA/β-ME) derivatives of analytes, 
following separation using HPLC (150). All analyte standards and samples were 
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derivatized prior to analysis. The sample preparation procedure was based on a 
published method (151, 152) with modification. A reduction step was used to convert the 
bound homocysteine form to free thiol form, which was maintained in the reduced state 
by 100 µL of 1% β-ME in 0.04 M sodium borate solution, pH 9.5, at 37ºC for 30 min. 
The remaining protein was then precipitated using 100µL of 1.5 M HClO4 as the 
precipitating reagent and 50 µL of 2 M K2CO3 as the neutralizing agent. Before 
derivatization with OPA/β-ME solution, 200 µL of mixture comprised of 25mg OPA, 
625 µL methanol, 6.25 mL, 0.04 M pH 9.5 sodium borate solution, 25µL β-ME, 200µL 
brij® 35 solution 30%, and 50 µL of an iodoacetic acid solution were used to bind at the 
thiol moiety of homocysteine to the fluorophore for fluorescence detection. The 
iodoacetic acid solution consisted of 52 mg iodoacetate in 5 mL 0.04 M, pH 9.5, sodium 
borate solution. Homocysteine concentration in the samples was identified by the 
retention time as compared to elution time of authentic homocysteine standards (Figure 
7). Homocysteine concentration was quantified using an external standard by comparing 
sample peak areas with areas of diluted standards of known concentration (Figure 8).   
C - reactive protein assay 
The CRP concentration was measured by immunonephelometry within the 
clinical laboratory at Scott and White Hospital, Temple, Texas. The method used serum, 
and employed particle-enhanced immumonephelometry (Dade Behring) (153) to test 
antigen-antibody complex formed by human serum CRP and monoclonal anti-CRP 
antibody. In this assay system, the concentration of CRP is proportional to the intensity 
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of the scattered light. Therefore, the CRP concentration was determined by comparison 
with dilutions of a standard of known concentration.   
Serum paraoxonase activity assay 
The activity of PON1 was assayed by using freshly prepared phenylacetate 
(Sigma, St. Louis Mo) as substrate (154) and determined by spectrophotometric assay.  
Materials were held on ice until assayed at 25 ºC in a 20 mM Tris·HCl buffer, pH 8, 
containing 1 mM CaCl2 and 1 mM phenylacetate. Enzymatic activities were calculated 
based on the conversion of phenylacetate into phenyl in diluted serum as measured 
kinetically by the increase velocities from initial velocities at 270 nm. The enzyme 
activity was calculated by subtracting the increase in absorbance observed in a 
separately incubated blank in order to control for phenylacetate self hydrolysis. The 
slope of the linear portion of kinetic curve was normalized to total protein in the sample 
(Figure 10). An extinction coefficient for the reaction was 1310 M-1cm-1. One unit of 
PON1 activity was equal to 1µmol of phenylacetate hydrolysis/mL/min.   
Statistical analysis 
Data were analyzed using SPSS 14.0 software for Windows. Analyzed data were 
expressed as mean ± SD of appropriate unit notations unless otherwise noted. The 
effects of consumption of the different test ground beefs meals was estimated by 
ANOVA using a general linear model (GLM) for repeated measures (P <0.05) with test 
ground beef and study phase as classifying variables. The treatment block effect and 
phase effect were estimated by ANOVA using GLM for univariate (P < 0.05). The 
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model was simplified if study block and phase was found to be non-significant. A 
boxplot among each three diet treatments was used in analysis. 
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CHAPTER IV 
RESULTS 
 
Twenty-eight of the thirty recruited subjects successfully completed this study. 
Two subjects (3 and 23) were excluded for personal and health reasons. The average age 
of all subjects was 35.6 ± 11.2 (mean ± SD); the pre-study body weight (91.3 ± 2.2 kg) 
and post-study body weight (90.7 kg) were not different. Similarly, pre-study DEXA 
body fat (28.2%) and post-study DEXA body fat (27.8%) were not different. Serum 
concentrations of TC, LDL-C and HDL- C were determined by another student as a 
component of their thesis and are presented in Table 4. Overall mean baseline values for 
measured parameters were calculated using data from all three phases of the study. As 
shown in reference normal range (Table 3), all baseline mean values (Table 5) and final 
mean value fell within normal ranges. All final mean values of each measured parameter 
(Table 6) were similar to three test ground beefs as well as being similar to baseline 
values.  
Plasma glucose concentration, serum insulin, IRI and β-CFI, homocysteine, CRP 
and PON1 were analyzed for all subjects at the end of washout and diet treatment 
periods (Table 5 and 6) as mean value. Median values are not affected by outliers and 
are a better indication of central tendency. From median on all diet treatments, glucose, 
insulin, IRI, β-CFI and PON1 were decreased (Table 7, Figure 11-15, 17), whereas 
homocysteine concentration increased (Table 7, Figure16) by the test ground beefs. CRP 
concentration was increased when subjects consumed the low- and high-MUFA test 
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ground beefs and decreased when subjects consumed the mid-MUFA test ground beef 
(Table 7, Figure 15). 
This study design was a RCB design. The block effect in each measurement was 
tested. The average age for group 1 (block 1) and group 2 (block 2) was 34.7 ± 11.2 and 
36.5 ±11.3 yr, respectively, and there was no significant different between these two 
groups (p = 0.303). The p-value for block effect of glucose was 0.441, of insulin, 0.470, 
of IRI, 0.440, of β-CFI, 0.425, of homocysteine, 0.245; and of PON1 activity, 0.538 
(Table 8). These p-values were not < 0.05; therefore, treatment block 1 and treatment 
block 2 were similar, block effect for these measurements can be removed. The p-value 
of the block effect for CRP was 0.020, meaning that the treatment block affected the test 
results. In advance to know where is block effect in three treatments. Test treatment 
block effect for each of three treatments based on baseline and final is shown in Table 9. 
The p value for the low-MUFA diet for final was 0.02. This indicated that there was a 
treatment block effect for the final, low-MUFA diet. The boxplot of low-MUFA diet 
treatment for the treatment block data was showed that there were two outliers (Figure 
19) this was also shown in Q-Q plot (Figure 20).  
This study was of a crossover, repeated measurement design. Each subject 
finished treatments in all studied periods at a different time period, and each subject 
served as his own control. Each subject was randomly assigned to each treatment order 
(Phase). In order to exclude a phase effect, the phase effect was tested based on the 
baseline value. The significance level of the phase effect for baseline value of glucose 
was p = 0.271, for insulin p = 0.432, for IRI p = 0.391, for β-CFI p = 0.984, for CRP p = 
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0.822 and for paraoxonase p = 0.892 (Table 10). These p values were not < 0.05; hence 
there was no significant effect of phases. Thus the phase effects on glucose, insulin, IRI, 
β-CFI, CRP and paraoxonase were removed, and then the effect of treatment on these 
values were tested. The p value for homocysteine baseline was 0.000, meaning that the 
three phases did not have a similar effect. The p value of the phase effect for low-MUFA 
beef was 0.168, for mid-MUFA beef it was 0.109 and for the high-MUFA beef it was 
0.000 (Table 11). In high-MUFA diet, the mean value of homocysteine for phase 1 is 
15.140 ± 0.929 µmol/L, for phase 2 is 9.600 ± 0.747 µmol/L and for phase 3 is 10.567 ± 
0.828 µmol/L (Table 12). Hi MUFA diet has a greater mean value of homocysteine 
compare to other two diet treatment (Figure 21). In the normal Q-Q plot (Figure 22), 
three outliers—subject of 7 (6.1µmol/L), 24 (19.9 µmol/L) and 27(19.7 µmol/L)—for 
the high-MUFA diet appeared. These greatly affected the mean value of baseline value 
in the high-MUFA diet treatment. Habitual diet data for each subject were not 
completely recorded, and then there is no enough information to determine the cause of 
the different phase effects on the high-MUFA diet. Hence, the mean values of other two 
phases at baseline were used for these three subjects in place of the outlier. The overall 
result for all measurement of MUFA content effect among MUFA diet treatments is 
show in Table 13. 
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CHAPTER V 
DISCUSSION 
  
The overall purpose of this study was to investigate whether provision of ground 
beef with a fractionally higher MUFA content could lower or improve several ASCVD 
risk factors. Previous studies using non-whole food source of fatty acids found that SFA, 
especially myristic acid and palmitic acid, can increase total and LDL-C, while MUFA 
had the opposite result. Diets low in total fat, and therefore high in carbohydrate, 
increased blood TAG and lowered HDL-C (37, 42). Therefore, substitution of MUFA 
for SFA was expected to lower the cholesterol concentration, and hence lower ASCVD. 
However there is a lack of information about the effects of increasing dietary MUFA 
using the whole food of ground beef ASCVD risk factors.  
The results of this study are in accord with the original studies by Smith et al. 
(48) in mildly hypercholesterolemic men in which increasing beef intake significantly 
increased the concentration of the primary HDL apolipoprotein, ApoA1. A portion of the 
present study completed by another student determined that there was an increase 
diameter of HDL-C when the subjects consumed the additional ground beef. The boxplot 
shown in Figure 23-25 showed the central tendency of median, 25% and 75% percentile 
for cholesterol values. The central tendency of LDL-C was to increase when the low-
MUFA test ground beef was consumed and to decrease with consumption of the mid- 
and high-MUFA test ground beefs. Consumption of the high-MUFA test ground beef 
produced a greater decrease in LDL-C than the mid-MUFA test ground beef.  
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The fat composition of test ground beefs influenced HDL-C in an expected way. 
While, the central tendency for HDL-C was to increase with all diet treatments, the high-
MUFA test ground beef increased HDL-C more than the mid- and low-MUFA test 
ground beefs. Lastly, the central tendency of TC was to decrease with low-MUFA test 
ground beef consumption, while slightly increasing with consumption of the mid-MUFA 
test ground beef, and to be unchanged by the consumption of the high-MUFA test 
ground beef. Overall, addition of the high-MUFA test ground beef increased HDL-C and 
decreased LDL, while the central tendency of TC was to be similar before and after 
addition of ground beef to the diet. In previous studies (37, 39, 44) that compared diets 
enriched in either SFA or MUFA decreasing SFA or increasing MUFA in the diet 
decreased LDL-C and increased HDL-C as compared with a reduced SFA with different 
proportion of MUFA diet (155). The earlier study by Smith et al. (48), as well as the 
present study used healthy men with an average age of 35.6 and who underwent regular 
physical activity.  
Insulin resistance has been determined to be a risk for ASCVD. Insulin resistance 
is characterized by increased TAG and decreased plasma HDL-C. Obesity and physical 
inactivity aggravate insulin resistance. Previous studies indicates that high carbohydrate 
and low fat intake aggravate hyperglycemia as evidenced by increases in plasma TAG 
and reductions in plasma HDL-C (40-42). Compared with carbohydrate, oleic acid has 
no such effect (44, 156). However, a diet rich in MUFA has an effect on individual 
components of the HOMA score, specifically β-CFI, that SFA and PUFA rich diets do 
not (26). The findings in the present study showed that consumption of additional 
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ground beef, regardless of fat composition, decreased glucose, insulin and HOMA score 
components of IRI and β-CFI when compared to values obtained at baseline. All 
measured plasma TAG concentrations were in the normal range and were similar among 
the three dietary treatments. Lowering results indicate that MUFA improved the insulin 
resistance and lowered fasting glucose and insulin concentration. Our experiment 
subjects are normal-lipidemic with weight maintenance men consumed different ratio of 
MUFA content ground beef, and decreased metabolic indexes was shown in this study, it 
can be conclude that MUFA enriched ground beef has beneficial effect to lower insulin 
resistance. 
Homocysteinemia is associated with an increase risk for ASCVD even though it 
was not listed in NCEP. A high plasma homocysteine concentration is associated with 
several traditional risk factors. Dietary deficiency of the vitamins folic acid, vitamin B6 
and vitamin B12 have been considered as factors that play key roles in plasma 
homocysteine concentration. Methionine, an essential amino acid, greatly affects 
homocysteinemia. Ground beef furnishes the greatest percentage of animal protein with 
a high amount of methionine, thus, the dietary methionine status and amount of protein 
intake seemingly influence the plasma homocysteine concentration. In the present study, 
each of the three dietary treatments increased plasma homocysteine. The ground beef 
used in the present study was 110g beef patties with a total fat content of 24% by weight. 
Based on the USDA database, 110g raw ground beef with 24% fat contains 16.04 g 
protein, 24 g lipid, 0.305 g vitamin B6, 0 g folic acid, 2.11 g vitamin B12 and 1.82 g 
iron. There is a lack of folic acid in ground beef. Folic acid is a key cofactor in the 
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remethylation pathway for conversion of homocysteine to methionine and it lowers the 
plasma concentration of homocysteine. Thus increasing folic acid intake results in 
decreased plasma homocysteine. However, a recent large and long term intervention trial 
in women (157) found that reductions in plasma homocysteine concentration by folic 
acid supplementation had no effect on ASCVD events.  
Many studies have documented that CRP can be used as a marker for chronic 
vascular inflammation and that elevations in CRP can indicate the degree of ongoing 
atherosclerosis. However, CRP values can be changed by environmental, lifestyle and 
mild infection (e.g. a cold). Thus, a single increased CRP value cannot be a specific 
indicator for a particular disease. In the present study, CRP increased slightly from 1.56 
to 1.94 (+0.38) mg/L when the low-MUFA diet was consumed, from 1.92 to 2.03 
(+0.11) mg/L when the high-MUFA was consumed and decreased form 2.36 to 1.45 (– 
0.91) mg/L when the mid-MUFA was consumed. These CRP values were not 
significantly different among the three treatments. CRP value did not follow a trend 
from low-, mid- to high-MUFA test ground beef as did the cholesterol values discussed 
earlier. Based on AHA/CDC panel cutoff point of CRP value for ASCVD risk (1.0 
mg/dL for low risk, 1.0-3.0 mg/dL for average risk and >3.0 mg/dL for high risk), mean 
values remained in the average risk category following consumption of any of the test 
ground beefs. However, among individuals were some different responses. Following 
consumption of the low-MUFA test ground beef three individuals converted from an 
average risk classification to high risk classification. In the mid-MUFA test ground beef 
group, these individuals converted from average to high risk while one individual 
 
 36
converted from average to low risk. In the high-MUFA group there were no changes in 
the number of individuals in each risk category (Table 14).  
Paraoxonase has been reported to play an antioxidative function that lowers the 
risk of ASCVD. Its activity is affected by genetic, environmental and developmental 
factors such as age. Dietary fatty acid intake is known to alter serum PON1 activity (28). 
The present study result showed that consumption of any of the test ground beefs 
decreased PON1 activity. In order to more fully evaluate these results, the ratio of PON1 
activity: HDL concentration was calculated. A decreased ratio of PON1 activity: HDL-C 
was observed after consumption of the test ground beefs (Figure 18). Also, most of 
PON1 values fell in the normal range (Table 15). The number of individuals with PON1 
activity in the lower normal range was increased after each dietary treatment. Following 
consumption of the high-MUFA test ground beef more subjects tended to have PON1 
activity that was in the lower than normal range. This reduced activity was unexpected. 
A previous study indicated that diet affects PON1 activity, being reduced by 
consumption of used-cooking fat containing more oxidized fat (114). Furthermore, 
another study showed reduced PON1 activities in women consuming a diet high in 
vegetable enriched with PUFA (158). Interestingly, reduced PON1 activity was found in 
transgenic rabbits over-expressing human ApoA1 and possessing a high concentration of 
HDL-C (159). A recent study found that a negative relationship of homocysteine and 
PON1 activity (160). Furthermore, a clinical study indicated that reduced PON1 activity 
was associated with normal HDL concentration in acute infarction patients (161, 162). 
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Therefore, it is a reasonable to suggest that PON1 activity can be reduced with oleic acid 
provided in ground beef. 
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CHAPTER VI 
CONCLUSION 
 
Measurement of plasma glucose, insulin, insulin resistance and β-cell function 
index showed that these metabolic indexes were decreased by consumption of an 
additional 114g of 24% fat ground beef five times per week regardless of fat 
composition. Thus increased beef consumption improved insulin sensitivity in normal-
lipemic, weight stable men. Together with previous study results obtained in this 
laboratory of reducing LDL-C, increasing the ratio of HDL-C/LDL-C and decreasing 
TAG it can be conclude that dietary MUFA have the beneficial effect to lower the risk of 
metabolic index for ASCVD. Improved insulin sensitivity is often accompanied by 
reduced inflammation; however, measurement of homocysteine and CRP concentrations, 
and PON1 activity in HDL suggested that this was not the case. Increased ground beef 
consumption increased the concentration of pro-oxidative amino acid homocysteine and 
reduced the activity of the antioxidative enzyme PON1 that is associated with HDL. This 
latter effect was best shown by the reductions in the PON1: HDL-C observed following 
5 weeks of ground beef consumption. Interestingly, there was a progressively greater 
reduction in PON1: HDL-C with increasing fractional MUFA content in the test ground 
beefs. This is a new finding that is greatly different from those of previous studies. 
While these results need to be confirmed by others, these new findings suggest that 
whole food dietary fatty acid sources have a more complex relationship to vascular 
health than previously thought and require further study. 
 
 39
REFERENCES 
 
1. Callow AD. Cardiovascular disease 2005--the global picture. Vascul Pharmacol 
2006;45:302-7. 
 
2. Lusis AJ. Atherosclerosis. Nature 2000;407:233-41. 
 
3. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74. 
 
4. Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Am J Pathol 
1977;86:675-84. 
 
5. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 
1993;362:801-9. 
 
6. Walzem RL, Watkins S, Frankel EN, Hansen RJ, German JB. Older plasma 
lipoproteins are more susceptible to oxidation: a linking mechanism for the lipid 
and oxidation theories of atherosclerotic cardiovascular disease. Proc Natl Acad 
Sci U S A 1995;92:7460-4. 
 
7. Williams KJ, Tabas I. The response-to-retention hypothesis of early 
atherogenesis. Arterioscler Thromb Vasc Biol 1995;15:551-61. 
 
8. Chisolm GM, Steinberg D. The oxidative modification hypothesis of 
atherogenesis: an overview. Free Radic Biol Med 2000;28:1815-26. 
 
9. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint 
distribution of non-HDL and LDL cholesterol and coronary heart disease risk 
prediction among individuals with and without diabetes. Diabetes Care 
2005;28:1916-21. 
 
10. Wilson PW. High-density lipoprotein, low-density lipoprotein and coronary 
artery disease. Am J Cardiol 1990;66:7A-10A. 
 
11. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C. Raising high-
density lipoprotein cholesterol with reduction of cardiovascular risk: the role of 
nicotinic acid--a position paper developed by the European Consensus Panel on 
HDL-C. Curr Med Res Opin 2004;20:1253-68. 
 
12. James T, Hein J, W, Jay N, David R. Management of Cholesterol Disorders 
Cardiovascular Medicine, Third Edition 2007:2667-91. 
 
 
 40
13. Rifai N, Ridker PM. Inflammatory markers and coronary heart disease. Curr 
Opin Lipidol 2002;13:383-9. 
 
14. Hornstra G, Barth CA, Galli C, et al. Functional food science and the 
cardiovascular system. Br J Nutr 1998;80 Suppl 1:S113-46. 
 
15. Eikelboom JW, Lonn E, Genest J, Jr., Hankey G, Yusuf S. Homocyst(e)ine and 
cardiovascular disease: a critical review of the epidemiologic evidence. Ann 
Intern Med 1999;131:363-75. 
 
16. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial 
cell injury in vitro: a model for the study of vascular injury. Thromb Res 
1980;18:113-21. 
 
17. Woo KS, Sanderson JE, Sun YY, et al. Hyperhomocyst(e)inemia is a risk factor 
for arterial endothelial dysfunction in humans. Circulation 2000;101:E116. 
 
18. Chen C, Halkos ME, Surowiec SM, Conklin BS, Lin PH, Lumsden AB. Effects 
of homocysteine on smooth muscle cell proliferation in both cell culture and 
artery perfusion culture models. J Surg Res 2000;88:26-33. 
 
19. Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. 
Med Clin North Am 2000;84:149-61, ix. 
 
20. Mosca L. C-reactive protein--to screen or not to screen? N Engl J Med 
2002;347:1615-7. 
 
21. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. 
Cardiol Clin 2003;21:315-25. 
 
22. Rifai N. C-reactive protein and coronary heart disease: diagnostic and therapeutic 
implications for primary prevention. Cardiovasc Toxicol 2001;1:153-7. 
 
23. Abrams J. C-reactive protein, inflammation, and coronary risk: an update. 
Cardiol Clin 2003;21:327-31. 
 
24. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk 
assessment in the primary prevention of cardiovascular disease. Circulation 
2001;103:1813-8. 
 
25. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and 
cardiovascular disease: application to clinical and public health practice: a 
statement for healthcare professionals from the Centers for Disease Control and 
Prevention and the American Heart Association. Circulation 2003;107:499-511. 
 
 41
 
26. Rojo-Martinez G, Esteva I, Ruiz de Adana MS, et al. Dietary fatty acids and 
insulin secretion: a population-based study. Eur J Clin Nutr 2006;60:1195-200. 
 
27. Salas J, Lopez Miranda J, Jansen S, et al. [The diet rich in monounsaturated fat 
modifies in a beneficial way carbohydrate metabolism and arterial pressure]. 
Med Clin (Barc) 1999;113:765-9. 
 
28. Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the 
development of the fatty streak. A review based on the 1994 George Lyman Duff 
Memorial Lecture. Arterioscler Thromb Vasc Biol 1996;16:831-42. 
 
29. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits 
three steps in the formation of mildly oxidized low density lipoprotein: step 1. J 
Lipid Res 2000;41:1481-94. 
 
30. Navab M, Hama SY, Anantharamaiah GM, et al. Normal high density lipoprotein 
inhibits three steps in the formation of mildly oxidized low density lipoprotein: 
steps 2 and 3. J Lipid Res 2000;41:1495-508. 
 
31. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new 
therapeutic target at the crossroads of dyslipidemia, inflammation, and 
atherosclerosis. Pharmacol Rev 2006;58:342-74. 
 
32. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease 
inhibition and complement activation in the antiinflammatory properties of HDL. 
J Clin Invest 2007;117:746-56. 
 
33. Berglund L, Oliver EH, Fontanez N, et al. HDL-subpopulation patterns in 
response to reductions in dietary total and saturated fat intakes in healthy 
subjects. Am J Clin Nutr 1999;70:992-1000. 
 
34. Patsch JR, Gotto AJ. Metabolism of high density lipoproteins. New 
Comprehensive Biochemistry 1987;14:221-259. 
 
35. Yang Y, Yan B, Fu M, Xu Y, Tian Y. Relationship between plasma lipid 
concentrations and HDL subclasses. Clin Chim Acta 2005;354:49-58. 
 
36. Fellin R, Baroni L, Baiocchi MR, Baldo Enzi G, Grego F, Valerio G. Selective 
determination of cholesterol in high density lipoprotein subfractions (HDL2 and 
HDL3) in patients with cerebral and peripheral arteriosclerosis. Clin Chim Acta 
1985;147:233-40. 
 
 
 42
37. Grundy SM. Influence of stearic acid on cholesterol metabolism relative to other 
long-chain fatty acids. Am J Clin Nutr 1994;60:986S-990S. 
 
38. Allman-Farinelli MA, Gomes K, Favaloro EJ, Petocz P. A diet rich in high-oleic-
acid sunflower oil favorably alters low-density lipoprotein cholesterol, 
triglycerides, and factor VII coagulant activity. J Am Diet Assoc 2005;105:1071-
9. 
 
39. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J 
Lipid Res 1990;31:1149-72. 
 
40. Starc TJ, Shea S, Cohn LC, Mosca L, Gersony WM, Deckelbaum RJ. Greater 
dietary intake of simple carbohydrate is associated with lower concentrations of 
high-density-lipoprotein cholesterol in hypercholesterolemic children. Am J Clin 
Nutr 1998;67:1147-54. 
 
41. Jeppesen J, Schaaf P, Jones C, Zhou MY, Chen YD, Reaven GM. Effects of low-
fat, high-carbohydrate diets on risk factors for ischemic heart disease in 
postmenopausal women. Am J Clin Nutr 1997;65:1027-33. 
 
42. Abbasi F, McLaughlin T, Lamendola C, et al. High carbohydrate diets, 
triglyceride-rich lipoproteins, and coronary heart disease risk. Am J Cardiol 
2000;85:45-8. 
 
43. Taskinen MR. Quantitative and qualitative lipoprotein abnormalities in diabetes 
mellitus. Diabetes 1992;41 Suppl 2:12-7. 
 
44. Mensink RP, Katan MB. Effect of monounsaturated fatty acids versus complex 
carbohydrates on high-density lipoproteins in healthy men and women. Lancet 
1987;1:122-5. 
 
45. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive 
value of total and HDL cholesterol in determining risk of first myocardial 
infarction. Circulation 1998;97:2007-11. 
 
46. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and 
carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids 
and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 
2003;77:1146-55. 
 
47. Sturdivant CA, Lunt DK, Smith GC, Smith SB. Fatty acid composition of 
subcutaneous and intramuscular adipose tissues and M. longissimus dorsi of 
Wagyu cattle. Meat Science 1992;32:449-458. 
 
 
 43
48. Smith DR, Wood R, Tseng S, Smith SB. Increased beef consumption increases 
apolipoprotein A-I but not serum cholesterol of mildly hypercholesterolemic men 
with different levels of habitual beef intake. Exp Biol Med (Maywood) 
2002;227:266-75. 
 
49. Wang MF, Yamamoto S, Chung HM, et al. Antihypercholesterolemic effect of 
undigested fraction of soybean protein in young female volunteers. J Nutr Sci 
Vitaminol (Tokyo) 1995;41:187-95. 
 
50. Grundy SM, Abrams JJ. Comparison of actions of soy protein and casein on 
metabolism of plasma lipoproteins and cholesterol in humans. Am J Clin Nutr 
1983;38:245-52. 
 
51. Williams PT, Krauss RM, Kindel-Joyce S, Dreon DM, Vranizan KM, Wood PD. 
Relationship of dietary fat, protein, cholesterol, and fiber intake to atherogenic 
lipoproteins in men. Am J Clin Nutr 1986;44:788-97. 
 
52. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of 
soy protein intake on serum lipids. N Engl J Med 1995;333:276-82. 
 
53. Schendel HE, Hansen JD. Studies on fat metabolism in kwashiorkor. I. Total 
serum cholesterol. Metabolism 1958;7:731-41. 
 
54. Loschiavo C, Ferrari S, Panebianco R, et al. Effect of protein-restricted diet on 
serum lipids and atherosclerosis risk factors in patients with chronic renal failure. 
Clin Nephrol 1988;29:113-8. 
 
55. Murphy-Chutorian DR, Wexman MP, Grieco AJ, et al. Methionine intolerance: a 
possible risk factor for coronary artery disease. J Am Coll Cardiol 1985;6:725-
30. 
 
56. McCully KS. Vascular pathology of homocysteinemia: implications for the 
pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28. 
 
57. Licastro F, Candore G, Lio D, et al. Innate immunity and inflammation in ageing: 
a key for understanding age-related diseases. Immun Ageing 2005;2:8. 
 
58. Shah PK. Pathophysiology of plaque rupture and the concept of plaque 
stabilization. Cardiol Clin 2003;21:303-14, v. 
 
59. Constantinides P. Atherosclerosis--a general survey and synthesis. Surv Synth 
Pathol Res 1984;3:477-98. 
 
 
 44
60. Harrison DG, Cai H. Endothelial control of vasomotion and nitric oxide 
production. Cardiol Clin 2003;21:289-302. 
 
61. Walzem RL. Chronic disease: long-term outcomes of metabolic dysfunction. 
Trends in Food Science & Technology 2004;15:519-527. 
 
62. Michael S. Brown JLG. How LDL Receptors Influence Cholesterol and 
Atherosclerosis.58-66. 
 
63. Kroon PA, Powell EE. Liver, lipoproteins and disease: I. Biochemistry of 
lipoprotein metabolism. J Gastroenterol Hepatol 1992;7:214-24. 
 
64. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and 
antioxidants in oxidative modification of LDL. Free Radical Biology and 
Medicine 1992;13:341-390. 
 
65. Michael S. Brown JLG. A receptor-mediated pathway for cholesterol 
homeostasis. Nobel lecture, Physiology or Medicine, 1985:284-324. 
 
66. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and 
antioxidants in oxidative modification of LDL. Free Radic Biol Med 
1992;13:341-90. 
 
67. Felix C Tanner  MRT, Thomas F Lüscher Endothelium, lipoproteins and 
atherosclerotic vascular disease. Vascular Medicine 1991;2:161-176. 
 
68. Kruth HS. Lipoprotein cholesterol and atherosclerosis. Curr Mol Med 
2001;1:633-53. 
 
69. Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of 
oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit 
and man. J Clin Invest 1989;84:1086-95. 
 
70. Esterbauer H, Jurgens G, Quehenberger O, Koller E. Autoxidation of human low 
density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and 
generation of aldehydes. J Lipid Res 1987;28:495-509. 
 
71. Hoff HF, O'Neil JA. Oxidation of LDL: role in atherogenesis. Klin Wochenschr 
1991;69:1032-8. 
 
72. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond 
cholesterol. Modifications of low-density lipoprotein that increase its 
atherogenicity. N Engl J Med 1989;320:915-24. 
 
 
 45
73. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular prevention. 
Eur J Intern Med 2006;17:77-80. 
 
74. Auerbach BJ, Kiely JS, Cornicelli JA. A spectrophotometric microtiter-based 
assay for the detection of hydroperoxy derivatives of linoleic acid. Analytical 
Biochemistry 1992;201:375-380. 
 
75. Yu J, Wang L, Walzem RL, Miller EG, Pike LM, Patil BS. Antioxidant activity 
of citrus limonoids, favonoids, and coumarins. J. Agric. Food Chem. 
2005;53:2009-2014. 
 
76. Yu J, Smith G, Gross HB, Hansen RJ, Levenberg J, Walzem RL. Enzymatic O-
methylation of flavanols changes lag time, propagation rate, and total oxidation 
during in vitro model triacylglycerol-rich lipoprotein oxidation. J. Agric. Food 
Chem. 2006;54:8403-8408. 
 
77. Himsworth H. Diabetes mellitus: a differentiation into insulin-sensitive and 
insulin-insensitive types. Lancet 1936;1:127-30 
 
78. Grundy SM. Metabolic syndrome: therapeutic considerations. Handb Exp 
Pharmacol 2005:107-33. 
 
79. Gotto AM. NCEP ATP III guidelines incorporate global risk assessment. Am J 
Manag Care 2003;Suppl:1, 3. 
 
80. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed 
hydrogen peroxide generation from homocysteine. J Clin Invest 1986;77:1370-6. 
 
81. Radomski MW, Salas E. Nitric oxide--biological mediator, modulator and factor 
of injury: its role in the pathogenesis of atherosclerosis. Atherosclerosis 1995;118 
Suppl:S69-80. 
 
82. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of 
homocysteine are modulated by endothelium-derived relaxing factor and related 
oxides of nitrogen. J Clin Invest 1993;91:308-18. 
 
83. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 
1998;338:1042-50. 
 
84. Gerhard GT, Duell PB. Homocysteine and atherosclerosis. Curr Opin Lipidol 
1999;10:417-28. 
 
 
 46
85. Vrentzos GE, Papadakis JA, Malliaraki N, et al. Diet, serum homocysteine levels 
and ischaemic heart disease in a Mediterranean population. Br J Nutr 
2004;91:1013-9. 
 
86. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-
reactive protein levels in obese postmenopausal women. Circulation 
2002;105:564-9. 
 
87. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using 
high-sensitivity C-reactive protein and lipid screening. Clin Chem 2001;47:28-
30. 
 
88. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive 
protein and low-density lipoprotein cholesterol levels in the prediction of first 
cardiovascular events. N Engl J Med 2002;347:1557-65. 
 
89. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of 
pravastatin on plasma concentration of C-reactive protein. The Cholesterol and 
Recurrent Events (CARE) Investigators. Circulation 1999;100:230-5. 
 
90. Superko HR, King S, 3rd. Lipid management to reduce cardiovascular risk: a 
new strategy is required. Circulation 2008;117:560-8; discussion 568. 
 
91. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. 
Incidence of coronary heart disease and lipoprotein cholesterol levels. The 
Framingham Study. Jama 1986;256:2835-8. 
 
92. Hughes SD, Verstuyft J, Rubin EM. HDL deficiency in genetically engineered 
mice requires elevated LDL to accelerate atherogenesis. Arterioscler Thromb 
Vasc Biol 1997;17:1725-9. 
 
93. Davidson MH, Toth PP. High-density lipoprotein metabolism: potential 
therapeutic targets. Am J Cardiol 2007;100:n32-40. 
 
94. Rader DJ. High-density lipoproteins and atherosclerosis. Am J Cardiol 
2002;90:62i-70i. 
 
95. McPherson PA, Young IS, McKibben B, McEneny J. High density lipoprotein 
subfractions: isolation, composition, and their duplicitous role in oxidation. J 
Lipid Res 2007;48:86-95. 
 
96. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase 
(PON1) deficiency is associated with increased macrophage oxidative stress: 
studies in PON1-knockout mice. Free Radic Biol Med 2003;34:774-84. 
 
 47
 
97. Asztalos BF, Schaefer EJ. High-density lipoprotein subpopulations in pathologic 
conditions. Am J Cardiol 2003;91:12E-17E. 
 
98. Moren X, Deakin S, Liu ML, Taskinen MR, James RW. HDL subfraction 
distribution of paraoxonase-1 and its relevance to enzyme activity and resistance 
to oxidative stress. J Lipid Res 2008;49:1246-53. 
 
99. Camps J, Marsillach J, Joven J. Measurement of serum paraoxonase-1 activity as 
a potential biomarker for chronic liver impairment. Clin Chim Acta 
2007;386:114-5. 
 
100. Cabana VG, Reardon CA, Feng N, Neath S, Lukens J, Getz GS. Serum 
paraoxonase: effect of the apolipoprotein composition of HDL and the acute 
phase response. J Lipid Res 2003;44:780-92. 
 
101. Bradshaw G, Gutierrez A, Miyake JH, et al. Facilitated replacement of Kupffer 
cells expressing a paraoxonase-1 transgene is essential for ameliorating 
atherosclerosis in mice. Proc Natl Acad Sci U S A 2005;102:11029-34. 
 
102. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes 
pro-inflammatory during the acute phase response. Loss of protective effect of 
HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 
1995;96:2758-67. 
 
103. Shih DM, Gu L, Xia Y-R, et al. Mice lacking serum paraoxonase are susceptible 
to organophosphate toxicity and atherosclerosis. Nature 1998;394:284-287. 
 
104. Shih DM, Xia YR, Wang XP, et al. Combined serum paraoxonase 
knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation 
and atherosclerosis. J Biol Chem 2000;275:17527-35. 
 
105. Kiss E, Seres I, Tarr T, Kocsis Z, Szegedi G, Paragh G. Reduced paraoxonase1 
activity is a risk for atherosclerosis in patients with systemic lupus 
erythematosus. Ann N Y Acad Sci 2007;1108:83-91. 
 
106. Ferre N, Marsillach J, Camps J, et al. Paraoxonase-1 is associated with oxidative 
stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol 
2006;45:51-9. 
 
107. Tartan Z, Orhan G, Kasikcioglu H, et al. The role of paraoxonase (PON) enzyme 
in the extent and severity of the coronary artery disease in type-2 diabetic 
patients. Heart Vessels 2007;22:158-64. 
 
 
 48
108. Dirican M, Sarandol E, Serdar Z, Ocak N, Dilek K. Oxidative status and 
prevalent cardiovascular disease in patients with chronic renal failure treated by 
hemodialysis. Clin Nephrol 2007;68:144-50. 
 
109. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased 
immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the 
human artery wall with the progression of atherosclerosis. Arterioscler Thromb 
Vasc Biol 1997;17:1233-8. 
 
110. Mackness MI, Durrington PN, Ayub A, Mackness B. Low serum paraoxonase: a 
risk factor for atherosclerotic disease? Chem Biol Interact 1999;119-120:389-97. 
 
111. Kotur-Stevuljevic J, Spasic S, Jelic-Ivanovic Z, et al. PON1 status is influenced 
by oxidative stress and inflammation in coronary heart disease patients. Clin 
Biochem 2008. 
 
112. Kriska T, Marathe GK, Schmidt JC, McIntyre TM, Girotti AW. Phospholipase 
action of platelet-activating factor acetylhydrolase, but not paraoxonase-1, on 
long fatty acyl chain phospholipid hydroperoxides. J Biol Chem 2007;282:100-8. 
 
113. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase 
(PON1) activity. Biochem Pharmacol 2005;69:541-50. 
 
114. Sutherland WH, Walker RJ, de Jong SA, van Rij AM, Phillips V, Walker HL. 
Reduced postprandial serum paraoxonase activity after a meal rich in used 
cooking fat. Arterioscler Thromb Vasc Biol 1999;19:1340-7. 
 
115. de Roos NM, Schouten EG, Scheek LM, van Tol A, Katan MB. Replacement of 
dietary saturated fat with trans fat reduces serum paraoxonase activity in healthy 
men and women. Metabolism 2002;51:1534-7. 
 
116. Nguyen SD, Sok DE. Beneficial effect of oleoylated lipids on paraoxonase 1: 
protection against oxidative inactivation and stabilization. Biochem J 
2003;375:275-85. 
 
117. Shih DM, Gu L, Hama S, et al. Genetic-dietary regulation of serum paraoxonase 
expression and its role in atherogenesis in a mouse model. J Clin Invest 
1996;97:1630-9. 
 
118. Mackness M, Boullier A, Hennuyer N, et al. Paraoxonase activity is reduced by a 
pro-atherosclerotic diet in rabbits. Biochem Biophys Res Commun 
2000;269:232-6. 
 
119. Kritchevsky D. Diet and atherosclerosis. Am Heart J 1999;138:S426-30. 
 
 49
 
120. Coombes JS, Powers SK, Demirel HA, et al. Vitamin E deficiency fails to affect 
myocardial performance during in vivo ischemia-reperfusion. Int J Vitam Nutr 
Res 2000;70:293-300. 
 
121. Szponar L, Respondek W. [The role of nutrition in the development of 
circulatory system diseases]. Wiad Lek 1994;47:771-8. 
 
122. Rein D, Yokoyama WH, Xu R, Walzem RL, German JB. Dietary vitamin e in an 
atherogenic hamster model. Nutrition Research 1998;18:567-579. 
 
123. Hu FB, Manson JE, Willett WC. Types of dietary fat and risk of coronary heart 
disease: a critical review. J Am Coll Nutr 2001;20:5-19. 
 
124. Caggiula AW, Mustad VA. Effects of dietary fat and fatty acids on coronary 
artery disease risk and total and lipoprotein cholesterol concentrations: 
epidemiologic studies. Am J Clin Nutr 1997;65:1597S-1610S. 
 
125. Dreon DM, Fernstrom HA, Campos H, Blanche P, Williams PT, Krauss RM. 
Change in dietary saturated fat intake is correlated with change in mass of large 
low-density-lipoprotein particles in men. Am J Clin Nutr 1998;67:828-36. 
 
126. Bucci C, Seru R, Annella T, et al. Free fatty acids modulate LDL receptor 
activity in BHK-21 cells. Atherosclerosis 1998;137:329-40. 
 
127. Ruiz-Gutierrez V, Morgado N, Prada JL, Perez-Jimenez F, Muriana FJ. 
Composition of human VLDL triacylglycerols after ingestion of olive oil and 
high oleic sunflower oil. J Nutr 1998;128:570-6. 
 
128. Kris-Etherton PM, Pearson TA, Wan Y, et al. High-monounsaturated fatty acid 
diets lower both plasma cholesterol and triacylglycerol concentrations. Am J Clin 
Nutr 1999;70:1009-15. 
 
129. Gill JM, Brown JC, Caslake MJ, et al. Effects of dietary monounsaturated fatty 
acids on lipoprotein concentrations, compositions, and subfraction distributions 
and on VLDL apolipoprotein B kinetics: dose-dependent effects on LDL. Am J 
Clin Nutr 2003;78:47-56. 
 
130. Grundy SM. Role of low-density lipoproteins in atherogenesis and development 
of coronary heart disease. Clin Chem 1995;41:139-46. 
 
131. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density 
lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells 
and smooth muscle cells. Proc Natl Acad Sci U S A 1990;87:5134-8. 
 
 50
 
132. Drake TA, Hannani K, Fei HH, Lavi S, Berliner JA. Minimally oxidized low-
density lipoprotein induces tissue factor expression in cultured human endothelial 
cells. Am J Pathol 1991;138:601-7. 
 
133. Oomen CM, Feskens EJ, Rasanen L, et al. Fish consumption and coronary heart 
disease mortality in Finland, Italy, and The Netherlands. Am J Epidemiol 
2000;151:999-1006. 
 
134. Anderson RL, Wolf WJ. Compositional changes in trypsin inhibitors, phytic 
acid, saponins and isoflavones related to soybean processing. J Nutr 
1995;125:581S-588S. 
 
135. Goldberg AP, Lim A, Kolar JB, Grundhauser JJ, Steinke FH, Schonfeld G. 
Soybean protein independently lowers plasma cholesterol levels in primary 
hypercholesterolemia. Atherosclerosis 1982;43:355-68. 
 
136. RMG CKaH. Effects of dietary protein and carbohydrate on plasma cholesterol 
levels in relation to atherosclerosis. Journal of Food Science 1975;40:18-23. 
 
137. Tzonou A, Kalandidi A, Trichopoulou A, et al. Diet and coronary heart disease: a 
case-control study in Athens, Greece. Epidemiology 1993;4:511-6. 
 
138. Rifkind BM. Nutrient--high-density lipoprotein relationships: an overview. Prog 
Biochem Pharmacol 1983;19:89-109. 
 
139. Zulli A, Hare DL, Buxton BF, Black MJ. The combination of high dietary 
methionine plus cholesterol induces myocardial fibrosis in rabbits. 
Atherosclerosis 2006;185:278-81. 
 
140. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of 
myocardial infarction: relation with vitamins B6, B12, and folate. Am J 
Epidemiol 1996;143:845-59. 
 
141. Kok FJ, Schrijver J, Hofman A, et al. Low vitamin B6 status in patients with 
acute myocardial infarction. Am J Cardiol 1989;63:513-6. 
 
142. Vermaak WJ, Barnard HC, Potgieter GM, Theron HD. Vitamin B6 and coronary 
artery disease. Epidemiological observations and case studies. Atherosclerosis 
1987;63:235-8. 
 
143. Brattstrom L, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism 
in early-onset cerebral and peripheral occlusive arterial disease. Effects of 
pyridoxine and folic acid treatment. Atherosclerosis 1990;81:51-60. 
 
 51
 
144. Castro R, Rivera I, Blom HJ, Jakobs C, Tavares de Almeida I. Homocysteine 
metabolism, hyperhomocysteinaemia and vascular disease: an overview. J Inherit 
Metab Dis 2006;29:3-20. 
 
145. Brown KS, Huang Y, Lu ZY, Jian W, Blair IA, Whitehead AS. Mild folate 
deficiency induces a proatherosclerotic phenotype in endothelial cells. 
Atherosclerosis 2006;189:133-41. 
 
146. Li M, Chen J, Li YS, Feng YB, Gu X, Shi CZ. Folic acid reduces adhesion 
molecules VCAM-1 expession in aortic of rats with hyperhomocysteinemia. Int J 
Cardiol 2006;106:285-8. 
 
147. Mojtahedzadeh F, Kosaryan M, Mahdavi MR, Akbari J. The effect of folic acid 
supplementation in beta-thalassemia major: a randomized placebo-controlled 
clinical trial. Arch Iran Med 2006;9:266-8. 
 
148. Mackness MI. Why plasma should not be used to study paraoxonase. 
Atherosclerosis 1998;136:195-6. 
 
149. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 
Homeostasis model assessment: insulin resistance and beta-cell function from 
fasting plasma glucose and insulin concentrations in man. Diabetologia 
1985;28:412-9. 
 
150. Nekrassova O, Lawrence NS, Compton RG. Analytical determination of 
homocysteine: a review. Talanta 2003;60:1085-1095. 
 
151. Tcherkas YV, Denisenko AD. Simultaneous determination of several amino 
acids, including homocysteine, cysteine and glutamic acid, in human plasma by 
isocratic reversed-phase high-performance liquid chromatography with 
fluorimetric detection. J Chromatogr A 2001;913:309-13. 
 
152. Turnell DC, Cooper JD. Rapid assay for amino acids in serum or urine by pre-
column derivatization and reversed-phase liquid chromatography. Clin Chem 
1982;28:527-31. 
 
153. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity 
C-reactive protein assay. Clin Chem 1999;45:2136-41. 
 
154. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum 
paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. 
Drug Metab Dispos 1991;19:100-6. 
 
 
 52
155. Aro A, Pietinen P, Valsta LM, et al. Effects of reduced-fat diets with different 
fatty acid compositions on serum lipoprotein lipids and apolipoproteins. Public 
Health Nutr 1998;1:109-16. 
 
156. Paniagua JA, de la Sacristana AG, Sanchez E, et al. A MUFA-rich diet improves 
posprandial glucose, lipid and GLP-1 responses in insulin-resistant subjects. J 
Am Coll Nutr 2007;26:434-44. 
 
157. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on 
risk of cardiovascular events and total mortality among women at high risk for 
cardiovascular disease: a randomized trial. Jama 2008;299:2027-36. 
 
158. Rantala M, Silaste ML, Tuominen A, et al. Dietary modifications and gene 
polymorphisms alter serum paraoxonase activity in healthy women. J Nutr 
2002;132:3012-7. 
 
159. Boullier A, Hennuyer N, Tailleux A, et al. Increased levels of high-density 
lipoprotein cholesterol are ineffective in inhibiting the development of immune 
responses to oxidized low-density lipoprotein and atherosclerosis in transgenic 
rabbits expressing human apolipoprotein (apo) A-I with severe 
hypercholesterolaemia. Clin Sci (Lond) 2001;100:343-55. 
 
160. Ferretti G, Bacchetti T, Marotti E, Curatola G. Effect of homocysteinylation on 
human high-density lipoproteins: a correlation with paraoxonase activity. 
Metabolism 2003;52:146-51. 
 
161. Lakshman MR, Gottipati CS, Narasimhan SJ, Munoz J, Marmillot P, Nylen ES. 
Inverse correlation of serum paraoxonase and homocysteine thiolactonase 
activities and antioxidant capacity of high-density lipoprotein with the severity of 
cardiovascular disease in persons with type 2 diabetes mellitus. Metabolism 
2006;55:1201-6. 
 
162. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum 
paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 
1999;19:330-5. 
 
163. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for 
the National Cholesterol Education Program Adult Treatment Panel III 
Guidelines. J Am Coll Cardiol 2004;44:720-32. 
 
164. Scott M. Grundy e. Third Report of the Expert Panel on Detection, Evaluation, 
and Treatment of the High Blood Cholesterol in Adults (Adult Treatment Panel 
III): Executive Summary 2001. 
 
 
 53
APPENDIX A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 54
 
 
 
FIGURE 1. The pathological development of atherosclerotic and plaque formation.  
The figure represents the monocyte and macrophage that participate in the inflammation process. This is initiated by LDL accumulation and progression 
by macrophage cell uptakes Ox-LDL and continues to proliferate and differentiate to form foam cell in the artery wall. HDL has the anti-atherogenetic 
property and caused by reverse cholesterol transport and its enzyme. 
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FIGURE 2. Lipoprotein metabolism.                                                                                                          
Up: CM transfer cholesterol from intestine to liver;                                                                            
Middle: VLDL and LDL transfer cholesterol from liver to the body;                                                  
Bottom: HDL transfer excess cholesterol from body back to the liver. CE: Cholesterol Ester; TG: 
Triacylglycerol; LPL:  Lipoprotein Lipase; LDLr: LDL Receptor; LRP: Receptor-Related Protein; CETP: 
Cholesteryl Ester Transfer Protein; LCAT: Lecithin: Cholesterol Acyltransferase; HTGL: Hepatic 
Triglyceride Lipase; PLTP: Phospholipids Transfer Protein. 
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FIGURE 3. Homocysteine metabolism.  
SAM: S-Adenosyl-methionine, SAH: S-Adenosyl-homocysteine, H4-folate: tetrahydrofolate, 5-methyl H4-folate. Homocysteine is a sulfur containing 
amino acid formed via transsulfuration and remethylation pathway. 
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FIGURE 4. Paraoxonase (PON1) biological function. 
PON1 mainly produced in liver and associated with HDL and ApoA1 circulating in blood. It has the ability to inhibit LDL oxidation to form foam cell 
and reduce the lesion in the artery wall. 
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FIGURE 5. Experimental design.  
The experiment design is a randomized completely block, crossover and repeated measurement study design. Group 1 and Group 2 represent treatment 
block 1 and treatment block 2. There are three treatments, A, B and C.  “A” represents low-MUFA, “B” represents mid-MUFA and “C” represents high-
MUFA ground beef. Three treatments are randomly assigned within treatment block, each treatment once in each treatment block.  Each subject 
received all treatment (A, B and C) in randomized sequence. Each subject was randomly assigned to each treatment, and has his own control (baseline) 
in each treatment. 
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FIGURE 6. Experimental timeline.  
The study was done in crossover design and was conducted in three phases. The total duration is 24 weeks. 3 weeks for washout (baseline) with habitual 
diet; 5 weeks for intervention (final) with three different FA compositions of ground beef. There were two blood collections at the end of baseline and 
final period in each phase. There were three phases with different FA composition. 3 weeks habitual diet and 5 weeks intervention diet in each phase. 
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FIGURE 7-1. Chromatogram of HPLC analysis of human plasma homocysteine (Homocysteine peak).  
Figure A: Homocysteine standard was analyzed after an injection of 25µL of the derivatized homocysteine standard.  
Figure B: 100 µL human samples were derivatized with 200µl OPA/β-ME, injected volume 25ul. 
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FIGURE 7-2.  Chromatogram of HPLC analysis of human plasma homocysteine (Retention time).  
Human plasma homocysteine concentration was calculated by comparing peak areas of sample and diluted standard. Human sample peak was 
determined by retention time. 
 
 
 
 
 
 
61 
 
 62
 
                           
FIGURE 8. Homocysteine standard curve (one of several standard curves).  
Human plasma homocysteine concentration was calculated by comparing human sample with diluted homocysteine standard of known concentration. X 
axis indicates the concentration of standard; Y axis indicates the Area mV * min of homocysteine peak. This standard curve is the one of several 
standard curves. 
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FIGURE 9. The sandwich ELISA principle for insulin assay.  
Y represents the pre-incubate mouse anti-human insulin antibody (Ab);       represents human insulin;      represents biotinylated Ab to detect the human 
insulin; E represents enzyme HRP (streptavidin-horseradish peroxidase); S represents substrate (3, 3’, 5, 5’-tetramethylbenzidine in Buffer-TMB).  
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FIGURE 10. Paraoxonase assay kinetic curve.  
X axis indicates the time (5 second apart) after adding paraoxonase; Y axis indicates the phenol formed 
based on specific absorbance at 270 nm wavelength. In the bigger figure, there is showing a kinetic curve 
with time changing (the product was measured apart from 5 second, total time is 360 second). The smaller 
insertion figure was taken the first 80 seconds of this measurement from the bigger figure and to make a 
linear curve (phenol formed vs. Time); a straight line (R2=0.9961) indicates a linear portion is present in 
the paraoxonase kinetic curve at the first 80 seconds. 
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FIGURE 11. Glucose boxplot for three diet treatments.  
The central line in box represents the median value for glucose concentration (mg/dl), and the bottom and 
upper line of box represent the lower and upper quartile.  The two vertical lines outside the box extend to 
the smallest and largest observation 1.5 QR of the quartiles. The closed circle represents mild outlier. 26 
(28-P1B1 (108)) 11 (12-P1B1 (74)) 69 (14-p2b1 (74)) 76 (21-p2b1 (74)). 
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FIGURE 12. Insulin boxplot for three diet treatments.  
The central line in box represents the median value for insulin concentration (µU/ml), and the bottom and 
upper line of box represent the lower and upper quartile.  The two vertical lines outside the box extend to 
the smallest and largest observation 1.5 QR of the quartiles. The closed circle represents mild outlier, star 
presents extremely outlier. 
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FIGURE 13. Insulin resistance index boxplot for three diet treatments.  
The central line in box represents the median value of IRI, and the bottom and upper line of box represent 
the lower and upper quartile.  The two vertical lines outside the box extend to the smallest and largest 
observation 1.5 QR of the quartiles. The closed circle represents mild outlier, star presents extremely 
outlier. 
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FIGURE 14. β-cell function index boxplot for three diet treatments.  
The central line in box represents the median value for β-CFI, and the bottom and upper line of box 
represent the lower and upper quartile.  The two vertical lines outside the box extend to the smallest and 
largest observation 1.5 QR of the quartiles. The closed circle represents mild outlier, star presents 
extremely outlier. 
 
 
 
 
 
 
 69
                         
Hi MUFAMid MUFALow MUFA
Diet
30
25
20
15
10
5
0
C
-r
ea
ct
iv
e 
pr
ot
ei
n 
(m
g/
L
)
102 110 54167
45
166
35
138
17
82
62
8
64
27
Final
Baseline
Period
                      
FIGURE 15. C – reactive protein boxplot for three diet treatments.  
The central line in box represents the median value for CRP concentration (mg/dL), and the bottom and 
upper line of box represent the lower and upper quartile.  The two vertical lines outside the box extend to 
the smallest and larges observation 1.5 QR of the quartiles. The closed circle represents outlier, star 
presents extremely outlier. 
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FIGURE 16. Homocysteine boxplot for three diet treatments.  
The central line in box represents the median value for homocysteine concentration (µM/L), and the 
bottom and upper line of box represent the lower and upper quartile.  The two vertical lines outside the 
box extend to the smallest and largest observation 1.5 QR of the quartiles. The closed circle represents 
outlier, star presents extremely outlier. 
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FIGURE 17. Paraoxonase boxplot for three diet treatments.  
The central line in box represents the median value for glucose, and the bottom and upper line of box 
represent the lower and upper quartile.  The two vertical lines outside the box extend to the smallest and 
largest observation 1.5 QR of the quartiles. The closed circle represents outlier, star presents extremely 
outlier.  
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FIGURE 18. Paraoxonase/HDL boxplot for three diet treatments.  
The central line in box represents median value for paraoxonase concentration (KU/mmol), and the bottom 
and upper line of box represent the lower and upper quartile.  The two vertical lines outside the box extend 
to the smallest and largest observation 1.5 QR of the quartiles. The closed circle represents mild outlier, 
star presents extremely outlier. 
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FIGURE 19. Final CRP boxplot of low-MUFA diet for treatment block.  
Vertical axis indicates final CRP value in low MUFA diet treatment. The two vertical lines outside the box 
extend to the smallest and largest observation 1.5 QR of the quartiles. The closed circle represents mild 
outlier, star presents extremely outlier.  
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FIGURE 20. Final CRP Q-Q plot of low-MUFA diet.  
Horizontal indicates observed value. Vertical axis indicates Expected normal value.  
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FIGURE 21. Boxplot of homocysteine baseline value for three diet treatments.  
1 represents Low MUFA diet, 2 represents Mid MUFA diet and 3 presents Hi MUFA diet. Horizontal 
indicates 3 diet treatments. Vertical axis indicates baseline homocysteine value. The two vertical lines 
outside the box extend to the smallest and largest observation 1.5 QR of the quartiles. The closed circle 
represents mild outlier. 
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FIGURE 22. Q-Q plot of homocysteine baseline value for three diet treatments.  
1 represent Low MUFA diet, 2 represent Mid MUFA diet and 3 present Hi MUFA diet. 
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FIGURE 23. Total cholesterol boxplot for three diet treatments. 
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FIGURE 24. LDL-C boxplot for three diet treatments. 
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FIGURE 25. HDL-C boxplot for three diet treatments. 
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             TABLE 1 
             Human plasma lipoprotein classification.  
     Chylomicron                       VLDL                               IDL                              LDL                               HDL 
Density ( g/cm )                    < 0.95                     9.5-1.006                   1.006-1.019              1.019-1.063               1.063-1.21  
Component   
% Protein                              1.5-2.5                        5-10                             15-20                       20-25                        40-55 
% Phospholipids                     7-9                           15-20                              22                           15-20                       20-35 
% Cholesterol                         1-3                            5-10                                8                             7-10                          3-4 
% Triacylglycerol                 84-89                         50-65                              22                            7-10                          3-5 
 % Cholesterol ester                3-5                           10-15                              30                           35-40                          12  
Apolipoprotein                AI, AII, B48,             B100, CI-CIII, E              B100, CIII, E                  B100 , E                   AI, AII, D, E 
                                         CI-CIII, E                                                                                                                                 CI-CIII,  
Size (nm)                            75-1200                        30-80                            25-35                         18-25                       5-12 
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                                           TABLE 2  
                                           Dietary fatty acid composition. 
       g/114-g ground beef party                
Fatty acid 
           Low MUFA                 Mid MUFA              High MUFA 
14:0 (Myristic)                                    0.99                              0.97                          0.66                  
14:1 (myristoleic)                                0.28                              0.26                           0.22 
16:0 (Palmitic)                                    8. 78                              8.43                           7.89 
16:1 ( n-7 ) ( Palmitoleic)                    0.85                              0.83                           0.97 
18:0 ( Stearic )                                     5.57                              4.98                           4.31 
18:1 ( trans-11 ( trans-vaccenic )       1.06                               0.97                           0.69 
18:1 ( n-9 ) (oleic )                              10.07                            11.06                         13.25 
18:1 ( n-7 ) ( cis-vaccenic )                 0.29                              0.36                            0.46                 
18:2 ( n-6) ( linoleic )                          0.55                              0.49                            0.56 
18:3 ( n-3 )  ( α –linoleic)                    0.09                              0.04                            0.03 
18:2 ( cis-9, trans-11 )                         0.18                              0.13                            0.14 
18:2 (trans-10, cis-12 )                        0.04                              0.07                            0.09 
MUFA:SFA                                         0.71                               0.83                            1.10 
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                  TABLE 3 
                  Reference normal range and NCEP ATP III criteria. 
NCEP ATP III treatment criteria (79, 163, 164) Variable                                 Reference  
                                            normal  range 
 
 
   Category             Baseline LDL level      Recommended            Therapeutic 
                                                                     Goal (LDL)                 Goal 
Total cholesterol (164)            < 200mg/dL 
LDL-cholesterol (164)            <100 mg/dL            High risk: CHD or      ≥100 mg/dL              <100 mg/dL                <70mg/dL 
                                                                             CHD Equivalent                                   optional <70mg/dL 
                                                                            (10y risk > 20% )    
                                                                                                           
                                                                            Moderate high risk 
                                                                              2+ risk factors           ≥130 mg/dL              <130 mg/dL               <100mg/dL 
                                                                            10 y risk 10-20%                                   optional <100mg/dL 
                                                                            Moderate risk: 
                                                                              2+ risk factors           ≥130 mg/dL              <130 mg/dL                <100mg/dL 
                                                                             10 y risk >20%  
                                                                            Low risk:                     ≥160 mg/dL              <160 mg/dL          
0-1 risk factor        
HDL-cholesterol (164)            > 60 mg/dL                Risk                        <40mg/dL(man)    
                                                                                                                < 50mg/dL (woman)                       
Triacylglycerol (164)              <150  mg/dL                            
Glucose (mg/dl)                   < 110 mg/dL                                              
Insulin (µU/ml)                     5-20 µU/mL  
Homocysteine (µM/L)              5-15 µM/L 
C-reactive protein (mg/L)    0.068-8.2 mg/L 
Paraoxonase (KU/L)            53-186kU/L (118) 
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             TABLE 4 
             Cholesterol concentrationsa. 
 
 
 
 
 
 
 
                 
              
                        
              
                         
                            
       
      
    
aConcentrations were measured from previous study of same study. The results are presented  
Mean ± SD                
      Variable (mg/dL) Baseline                              Final                                 P value 
TG                                                                                                                         0.718 
           Low MUFA          124.32 ± 99.11                   114.96 ± 74.63        
           Mid MUFA           119.57 ± 81.38                   109.64 ± 68.38         
           Hi MUFA             135.75 ± 113.69                 149.86  ± 258.16           
 
Total-C                                                                                                                  0.39 
           Low MUFA          189.82 ± 36.81                   186.04 ± 33.17        
           Mid MUFA           188.14 ± 38.85                   190.18 ± 33.51         
           Hi MUFA             188.79 ± 34.29                   190.50 ± 37.74           
 
LDL-C                                                                                                                   0.57 
           Low MUFA         122.00 ± 34.28                    117.71± 29.58                       
           Mid MUFA          120.14 ± 32.76                    120.43 ± 33.30            
           Hi MUFA            122.18 ± 31.27                    121.46 ± 35.21            
 
HDL                                                                                                                       0.316 
           Low MUFA         46.82 ± 10.13                      47.36 ± 9.99 
           Mid MUFA          46.54 ± 8.90                       47.89 ±10.04 
           Hi MUFA            45.61 ± 10.98                      48.50 ± 10.67              
 
LDL/HDL                                                                                                             0.802 
           Low MUFA         2.77 ± 1.15                          2.67 ± 1.09                
           Mid MUFA          2.68 ± 0.89                          2.63± 0.93 
           Hi MUFA            2.86 ± 1.06                          2.71 ± 1.26                
 
Total-C/HDL                                                                                                         0.562 
           Low MUFA          4.26 ±1.33                          4.15 ± 1.32       
           Mid MUFA           4.16 ± 1.06                         4.16 ± 1.21     
           Hi MUFA             4.35 ±  1.25                        4.18 ± 1.50          
            as mean ± SD. 
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  TABLE 5   
  Baseline mean value of three diet measurements. Data presented as mean ± SD. 
Baseline  
Variable 
                    Mean ± SD                             Range 
Glucose (mg/dL)             
            Low MUFA                                       90.82 ± 6.80                        74-102 (28)                                     
            Mid MUFA                                       93.07 ± 6.24                        82-105(23) 
            High MUFA                                      91.11 ± 7.88                        74-108 (34) 
Insulin  (µU/mL)            
            Low MUFA                                       5.94 ± 3.64                          1.0-17.8 (16.8)  
            Mid MUFA                                        6.05 ± 4.55                          0.7-18.6 (17.9) 
            Hi MUFA                                          6.76 ± 6.34                        0.6-27.7 (27.6) 
IRI                                 
            Low MUFA                                       1.33 ± 0.80                          0.2-4.0 (3.8) 
            Mid MUFA                                        1.40 ± 1.06                          0.2-4.3(4.1) 
            Hi MUFA                                          1.53 ± 1.43                           0.1-6.0 (5.9) 
ß-CFI                             
            Low MUFA                                       82.85 ± 61.24                      17.3-237.3 (220) 
            Mid MUFA                                       73.50 ± 56.17                       6.5-240.5 (236) 
            Hi MUFA                                          92.14 ± 87.8                        6.5-398.5 (392) 
Homocysteine (µM/L)  
            Low MUFA                                      11.46 ± 3.48                         6.1-19.2 (13.1) 
            Mid MUFA                                       11.73 ± 3.31                         7.2-19.9 (12.7) 
            Hi MUFA                                         11.89 ± 3.52                          6.1-19.9 (13.8) 
CRP (mg/L)                  
            Low MUFA                                       1.56 ± 2.63                           0-12.4 (12.4) 
            Mid MUFA                                        2.36 ± 5.50                           0-29.3 (29.3) 
            Hi MUFA                                          1.92 ± 0.76                           0-12.2 (12.2) 
Paraoxonase (KU/L)      
            Low MUFA                                       57.08 ± 11.80                       26.72-90.99 (64.27) 
            Mid MUFA                                        56.43 ± 11.93                       25.45-76.93 (51.48) 
            Hi MUFA                                          59.05 ± 10.50                        43.61-72.60 (28.99) 
Paraoxonase/HDL (KU/mmol)      
            Low MUFA                                       1.28 ± 0.41                            26.72-90.99 (64.27)      
            Mid MUFA                                        1.27 ± 0.40                            25.45-76.93 (51.48) 
            Hi MUFA                                          1.38 ± 0.36                             43.61-72.60 (28.99) 
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  TABLE 6  
  Final mean value of three diet treatments. Data presented as mean ±SD. 
Final  
Variable 
                   Mean ± SD                             Range 
Glucose (mg/dL)             
            Low MUFA                                      90.00 ± 5.83                         80-101 (21)                
            Mid MUFA                                      90.86 ± 7.17                         76-107 (31)             
            High MUFA                                     91.00 ± 7.73                          73-109 (36) 
Insulin  (µU/mL)           
            Low MUFA                                      5.10 ± 4.63                            0.6-17.1 (16.5)           
            Mid MUFA                                       4.70 ± 3.76                            0.3-15.1 (14.8)       
            Hi MUFA                                          4.88 ± 4.35                            0.4-17.8 (17.4) 
IRI                                 
            Low MUFA                                      1.13 ± 1.02                             0.1-3.8 ( 3.7)                
            Mid MUFA                                       1.06 ± 0.88                             0.1-4.0 (3.9)           
            Hi MUFA                                          1.11 ± 1.03                             0.1-4.4 (4.3) 
ß-CFI                             
            Low MUFA                                      71.16  ± 67.97                         9.0-256.5 (247.5)        
            Mid MUFA                                       65.81 ± 71.77                          2.6-393.2 (390.6)   
            Hi MUFA                                          66.36 ± 66.38                          4.1-311.1 (307) 
Homocysteine (µM/L)  
            Low MUFA                                      12.56 ± 3.04                            7.9-20.8  (12.9)          
            Mid MUFA                                       12.31 ± 2.55                            7.2-18.4 (11.2)        
            Hi MUFA                                          12.52 ± 2.61                            7.6-17.1(9.5) 
CRP (mg/L)                  
            Low MUFA                                      1.94 ± 2.62                               0-10 (10)                      
            Mid MUFA                                       1.45 ± 2.14                               0-9.7 (9.7)                
            Hi MUFA                                          2.03 ± 2.88                               0-10.4 (10.4) 
Paraoxonase (KU/L)      
            Low MUFA                                       55.52 ± 11.52                           25.68-73.66 (47.98)    
            Mid MUFA                                       55.06 ± 11.28                            23.13-73.6 (50.47)   
            Hi MUFA                                          57.05 ± 10.82                            26.74-87.3 (60.56) 
Paraoxonase/HDL (KU/mmol)      
            Low MUFA                                       1.26 ± 0.38                               51.05-59.99 (8.94) 
            Mid MUFA                                       1.20 ± 0.39                                50.69-59.43 (8.74) 
            Hi MUFA                                          1.25 ± 0.46                               52.86-61.25 (8.39) 
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  Table 7  
  Median value of three diet measurements. 
Median ± SD   
Variable 
                Baseline                                Final 
Glucose (mg/dL)             
            Low MUFA                                    91.5 ± 6.80                           89.0 ± 5.83                           
            Med MUFA                                    94.0 ± 6.24                           91.5 ± 7.16  
            High MUFA                                   92.5 ± 6.80                           89.5 ± 7.73 
Insulin  (µU/mL)           
            Low MUFA                                    5.10 ± 3.64                           3.40 ± 4.63                              
            Mid MUFA                                     5.00 ± 4.55                           3.70 ± 3.76  
            Hi MUFA                                       4.65 ± 6.34                            3.8 ± 4.35 
IRI                                 
            Low MUFA                                    1.18 ± 0.79                            0.80 ± 1.02                                 
            Mid MUFA                                     1.12 ± 1.06                           0.87 ± 0.88  
            Hi MUFA                                       1.08 ± 1.43                            0.81 ± 1. 03 
ß-CFI                             
            Low MUFA                                     62.59 ± 61.24                       42.51 ± 67.97  
            Mid MUFA                                      62.39 ± 56.17                       46.71 ± 71.76 
            Hi MUFA                                        63.78 ± 87.81                        43.81 ± 66.38 
Homocysteine (µM/L)  
            Low MUFA                                     10.70 ± 3.48                         12.20 ± 3.03                              
            Mid MUFA                                      10.7 ± 3.31                           12.65 ± 2.55  
            Hi MUFA                                        11.45 ± 3.53                          12.15 ± 2.61 
CRP (mg/L)                 
            Low MUFA                                     .65 ± 2.62                              .70 ± 2.61                                 
            Mid MUFA                                      .75 ± 5.49                              .50 ± 2.14  
            Hi MUFA                                        .85 ± 3.04                               .90 ± 2.88 
Paraoxonase (KU/L)      
            Low MUFA                                     58.79 ± 11.79                        54.95±11.52                               
            Mid MUFA                                      58.41 ± 11.93                        57.25 ± 11.28  
            Hi MUFA                                         59.72 ± 7.20                          58.66 ± 10.82 
Paraoxonase/HDL (KU/mmol)      
            Low MUFA                                     1.26 ± 0.41                             1.22 ± 0.38 
            Mid MUFA                                      1.25 ± 0.40                             1.18  ± 0.39 
            Hi MUFA                                        1.40  ±  0.36                            1.17 ± 0.46 
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                     TABLE 8 
                     Treatment block effect of three diet measurements.  
Mean Variable 
         Treatment block 1            Treatment block 2 P-valuea 
Age                                                            34.7                                  36.5                                   0.303 
Glucose (mg/dL )                                      91.56                                 90.73                                0.441 
Insulin (µU/mL)                                        5.31                                   5.83                                  0.470 
IRI                                                             1.22                                   1.32                                  0.440 
β-CFI                                                         71.03                                 79.58                                0.425 
Homocysteine (µmol/L)                            11.80                                12.36                                 0.245 
C-reactive protein (mg/L)                         1.28                                   2.47                                   0.020 
Paraoxonase (KU/L)                                 56.27                                 57.30                                 0.538  
PON/HDL (KU/mmol)                             1.304                                 1.23                                   0.009 
                     a Treatment block effect was tested by GLM at P < .05. 
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                            TABLE 9 
                            Treatment block effect of C-reactive protein in three diet treatments. 
                                                      Mean ± SD 
Effect in               Treatment block 1                   Treatment block                     p-valuea 
Low MUFA diet 
       Baseline                              0.818 ± 1.40                            2.314 ±  3.37                          0.133 
       Final                                    0.821 ± 1.05                            3.064 ±  3.23                          0.02 
Mid MUFA diet 
       Baseline                              1.171 ± 1.198                          3.557 ± 7.63                           0.258 
       Final                                    1.007 ± 1.504                          1.900 ± 2.610                         0.278 
High MUFA diet 
       Baseline                              2.307 ± 0.818                           1.393 ± 0.818                         0.437 
       Final                                    1.528 ± 2.170                           2.569 ± 3.507                         0.359 
                        a Treatment block effect was tested by GLM at P < .05. 
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  TABLE 10    
  Phase effect for baseline values. 
Baseline value                                                Sum of Squares     Df         Mean Square          F              Siga 
 
Glucose ( mg/dL)              Between Groups         128.667            2              64.3331           0 .325        0.271 
                                          Within Groups            3932.000          81            48.543 
                                          Total                           4060.667          83 
Insulin (µU/mL)                Between Groups         41.355              2              20.678             0.849          0.432 
                                          Within Groups            1972.495          81             24.352 
                                          Total                            2013.850         83 
IRI                                     Between Groups         2.371                2               1.185              0.951          0.391 
                                          Within Groups            101.001            81             1.247 
                                          Total                           103.372            83  
β-CFI                                 Between Groups        5266.799           2               2633.399        0.541          0.584 
                                          Within Groups            394220.367      81              4866.918 
                                          Total                           399487.165      83 
Homocysteine (µM/L)       Between Groups        234.622             2               117.311           13.029      0 
                                           Within Groups          729.305             81               9.004 
                                           Total                          963.927            83 
C-reactive protein (mg/L)  Between Groups       6.102                 2                 3.051              0.197         0.822 
                                           Within Groups          1253.761           81               15.479 
                                           Total                         1259.862           83 
Paraoxonase (KU/L)          Between Group        25.727                2                 12.863            0.114        0.892 
                                           Within Groups          9123.533           81                112.636 
                                           Total                         9149.260           83 
Paraoxonase (KU/mmol)   Between Groups       0.304                 2                   0.152             1.003       0.371 
                                           Within Groups          12.263               81                  0.153 
                                           Total                         12.566               83 
  a It was tested by one way ANOVA.   
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                            TABLE 11 
                            Baseline phase effects of homocysteine for three diet treatments. 
 
Baseline value                             Sum of Squares        df             Mean Square           F                Siga 
 
Low MUFA    Between Groups       43.593                  2               21.797                   1.915           0.168 
                        Within Groups          284.553                25             11.382 
                        Total                         328.147                27  
Mid MUFA     Between Groups       48.282                  2               24.141                   2.424           0.109 
                        Within Groups          249.019                25             9.961 
                        Total                         297.301                 27   
High  MUFA  Between Groups       168.58                   2               84.291                  12.599          0 
                        Within Groups          167.264                25              6.691 
                        Total                         335.847                27 
                        a It was measured by ANOVA method. 
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                            TABLE 12 
                            Homocysteine baseline means value for three phases. 
Mean ± SEM Effect in 
    Phase  1                      Phase 2                      Phase 3                 Mean value for 3 phases 
Low MUFA diet               13.110 ± 1.135           10.278 ± 0.807          10.811 ± 3.900           11.461 ±3.486 
Mid MUFA diet                13.788 ± 1.629           10.690 ± 0.779          11.130 ± 0.713           11.732 ± 3.318    
High MUFA diet              15.140 ± 0.929            9.600 ± 0.747            10.567 ± 0.828           11.889 ± 3.527 
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TABLE 13  
Phase effect among three diet treatments for all measurements. 
Measurement                                       Sum of Squares          df          Mean Square            F               Sig. 
Glucose           Baseline-Final                 46.095                     1             46.095                  1.912         0.171  
                        Baseline-Final* Diet        32.155                     2             16.077                  0.667         0.516       
                        Error( Baseline-Final)     1952.75                   81            24.108       
    
Insulin             Baseline-Final                 77.493                     1              77.493                 6.97           0.010  
                        Baseline-Final* Diet        7.512                       2              3.756                  0.338         0.714 
                        Error( Baseline-Final)      900.58                    81            11.118  
         
IRI                   Baseline-Final                  4.212                       1             4.212                   7.404         0.008  
                        Baseline-Final* Diet         0.332                       2             0.166                   0.292         0.748 
                        Error( Baseline-Final)      46.076                      81          0.569       
    
Β-CFI              Baseline-Final                   9517.452                 1             9517.452             4.022        0.048  
                        Baseline-Final* Diet         2529.202                  2            1264.601              0.534        0.588 
                        Error( Baseline-Final)       191658.214             81           2366.151     
      
Homocysteine Baseline-Final                    24.994                     1             24.994                3.048        0.085  
                        Baseline-Final* Diet          2.290                        2             1.145                 0.140         0.870 
                        Error( Baseline-Final)       664.156                    81           8.199        
   
CRP                Baseline-Final                    0.817                       1              0.817                  0.145       0.002  
                        Baseline-Final* Diet         12.932                      2              6.466                  1.151       0.028 
                        Error( Baseline-Final)       449.580                   81            5.620        
  
Paraoxonase    Baseline-Final                   137.795                   1              137.795               2.955       0.089  
                        Baseline-Final* Diet          10.186                    2               5.093                   0.109       0.897 
                        Error( Baseline-Final)       3777.449                 81            46.635          
 
Paraoxonase    Baseline-Final                 0.277                        1               0.277                  6.413        0.013  
    /HDL          Baseline-Final* Diet       0.047                          2               0.023                 0.542         0.584 
                        Error( Baseline-Final)     3.495                        81             0.043          
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                                TABLE 14  
                                CRP risk rate among three MUFA diet treatmentsa. 
                                           Total number                    low risk                   average risk                 high risk 
 Low MUFA                  
       Baseline line                        28                                 17                                   8                             3 
       Final                                    28                                 17                                   5                             6 
Mid MUFA                                         
       Baseline line                        28                                 17                                    8                            3 
       Final                                    28                                 18                                    5                            5 
High MUFA                                        
       Baseline line                        28                                 16                                    7                            5 
       Final                                    27                                 15                                    7                            5 
                           a The number of risk based on the cutoff point CRP value, < 1.0 “low risk”, 1-3 “average risk” and >3.0 “high  
                                   risk”.  
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                         TABLE 15  
                         Paraoxonase activitya changing rate among three MUFA diet treatments. 
                       Number of value                              Paraoxonase activity 
                    Lower normal range                            Vary after treatment   
 
              Baseline                     final                       up                     down 
Low MUFA                                    8                             10                            10                       18 
Mid MUFA                                    9                             11                             12                       16 
High MUFA                                   5                              9                              12                       16 
                     a The normal activity of PON is 53-186kU/L. 
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